<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of metastatic urothelial carcinoma of the bladder and urinary tract</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of metastatic urothelial carcinoma of the bladder and urinary tract</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of metastatic urothelial carcinoma of the bladder and urinary tract</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joaquim Bellmunt, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Seth P Lerner, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 19, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Bladder cancer is the most common malignancy involving the urinary system. Urothelial carcinoma (UC) is the predominant histologic type in the United States and Europe. In other areas of the world, non-urothelial carcinomas are more frequent. Much less commonly, urothelial cancers can arise in the renal pelvis, ureter, or urethra.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2987.html" rel="external">"Malignancies of the renal pelvis and ureter"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2953.html" rel="external">"Urethral cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2957.html" rel="external">"Epidemiology and risk factors of urothelial (transitional cell) carcinoma of the bladder", section on 'Epidemiology'</a>.)</p><p></p><p>The approach to systemic therapy for locally advanced unresectable or metastatic UC of the bladder and urinary tract is evolving. Systemic treatment options include antibody drug-conjugates, chemotherapy, immune checkpoint inhibitors, and targeted therapies, as single agents or in combination. The goals of therapy include controlling tumor burden, treating cancer-related symptoms, and improving overall survival. Although treatment intent for most patients with bladder cancer is palliative, some patients may have a chance at curative intent therapy.</p><p>The treatment of metastatic UC of the bladder and urinary tract is presented here. Other topics related to the management of locally advanced muscle-invasive urothelial carcinoma of the bladder cancer are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2974.html" rel="external">"Radical cystectomy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2991.html" rel="external">"Neoadjuvant treatment options for muscle-invasive urothelial bladder cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2966.html" rel="external">"Adjuvant therapy for muscle-invasive urothelial carcinoma of the bladder"</a>.)</p><p></p><p class="headingAnchor" id="H2740504"><span class="h1">PROGNOSTIC FACTORS</span><span class="headingEndMark"> — </span>Some clinical and molecular factors correlate with prognosis in metastatic urothelial carcinoma. Such prognostic factors can be used to determine which patients may benefit from therapy. (See <a class="local">'Defining eligibility for systemic therapy'</a> below.)</p><p class="headingAnchor" id="H1495807775"><span class="h2">Clinical factors</span><span class="headingEndMark"> — </span>Clinical factors associated with decreased survival in metastatic urothelial carcinoma (UC) include:</p><p class="bulletIndent1"><span class="glyph">●</span>Karnofsky Performance Status of less than 80 percent  (<a class="graphic graphic_table graphicRef58785" href="/d/graphic/58785.html" rel="external">table 1</a>) [<a href="#rid1">1-4</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Visceral metastases (ie, lungs, liver, bone) [<a href="#rid1">1-9</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Low hemoglobin levels [<a href="#rid9">9</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Shorter duration among lines of therapy [<a href="#rid10">10</a>]</p><p></p><p class="headingAnchor" id="H1495807782"><span class="h2">Molecular factors</span><span class="headingEndMark"> — </span>Specific molecular alterations within the tumor are also being studied to help select treatment and predict survival outcomes.</p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>FGFR2</em></strong><strong> or </strong><strong><em>FGFR3</em></strong> – Tumors that express a fibroblast growth factor receptor (<em>FGFR</em>) 3 or 2 genetic alterations respond to the <em>FGFR</em> inhibitor <a class="drug drug_general" data-topicid="121054" href="/d/drug information/121054.html" rel="external">erdafitinib</a> after progression on a platinum-based chemotherapy regimen. Further details are discussed separately. (See <a class="local">'Erdafitinib'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other molecular alterations </strong>– Other molecular factors have also been assessed but are not validated for clinical use [<a href="#rid11">11-13</a>]. (See  <a class="medical medical_review" href="/d/html/118610.html" rel="external">"Molecular biology of bladder cancer"</a>.)</p><p></p><p class="headingAnchor" id="H3"><span class="h1">INITIAL THERAPY</span><span class="headingEndMark"> — </span>The approach to initial therapy for patients with metastatic urothelial cancer (UC) of the bladder and urinary tract is evolving  (<a class="graphic graphic_algorithm graphicRef111737" href="/d/graphic/111737.html" rel="external">algorithm 1</a>). Selection of therapy is based upon patient eligibility for systemic therapy (platinum-based chemotherapy, immunotherapy), performance status, and comorbidities. Clinical trial enrollment is encouraged, where available.</p><p class="headingAnchor" id="H3687777977"><span class="h2">Defining eligibility for systemic therapy</span><span class="headingEndMark"> — </span>All patients who are candidates for systemic therapy (chemotherapy, immunotherapy, and/or targeted therapy) should undergo evaluation of their suitability to tolerate therapy. Important factors to evaluate include age, performance status, concurrent comorbidities, and organ function (including cognitive function assessment). The selection of therapy should incorporate the patient's performance status and ability to tolerate therapy. An assessment that incorporates physiologic and biologic considerations can stratify patients into medically "fit" and "frail" populations, which are used to determine treatment options. This stratification of medically "fit" and "frail" is frequently used to classify patients in clinical trials but may eventually be redefined as therapy evolves and becomes well tolerated across different populations. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cisplatin</strong><strong> eligibility</strong> – Patients being evaluated for cisplatin-based chemotherapy should also undergo assessment of kidney function, the presence of hearing loss and/or peripheral neuropathy (all of which could be adversely affected by <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>), and heart failure status (which determines the patient's ability to tolerate the fluid administered concurrently with cisplatin). For patients with impaired kidney function, reversible causes (eg, urinary tract obstruction secondary to a tumor mass) should be identified and treated prior to initiation of cisplatin-based therapy.</p><p></p><p class="bulletIndent1">Patients who are medically fit and eligible for cisplatin-based combination chemotherapy meet all of the criteria below  (<a class="graphic graphic_table graphicRef143615" href="/d/graphic/143615.html" rel="external">table 2</a>) [<a href="#rid14">14</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>World Health Organization (WHO)/Eastern Cooperative Oncology Group (ECOG) performance status less than 2  (<a class="graphic graphic_table graphicRef72901" href="/d/graphic/72901.html" rel="external">table 3</a>) or a Karnofsky Performance Status greater than 70 percent  (<a class="graphic graphic_table graphicRef58785" href="/d/graphic/58785.html" rel="external">table 1</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Creatinine clearance greater than or equal to 60 mL/minute</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>No significant hearing loss (measured at audiometry of 25 dB at two contiguous frequencies)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Grade &lt;2 peripheral neuropathy (ie, sensory alteration or paresthesia, including tingling, but not interfering with activities of daily living)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>No clinical evidence of New York Heart Association class III or greater heart failure  (<a class="graphic graphic_table graphicRef52683" href="/d/graphic/52683.html" rel="external">table 4</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Carboplatin</strong><strong> eligibility</strong> – Patients who are candidates for carboplatin-based chemotherapy may have appropriate performance status but otherwise be ineligible for cisplatin-based combination chemotherapy due to kidney dysfunction, neuropathy, severe hearing loss, neuropathy, and/or heart failure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunotherapy eligibility</strong> – Patients being evaluated for immunotherapy should also undergo assessment for autoimmune conditions, infectious disorders, and previous exposure to immunomodulating agents (ie, steroids) and antibiotics. Further details on eligibility for immunotherapy are discussed separately. (See  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'Defining immunotherapy eligibility'</a>.)</p><p></p><p class="headingAnchor" id="H421227779"><span class="h2">Platinum-eligible</span></p><p class="headingAnchor" id="H533860610"><span class="h3">Enfortumab vedotin plus pembrolizumab</span><span class="headingEndMark"> — </span>For patients with advanced or metastatic UC who are eligible for platinum-based (ie, <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> or <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a>) chemotherapy, we recommend <a class="drug drug_general" data-topicid="126407" href="/d/drug information/126407.html" rel="external">enfortumab vedotin</a> plus <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> rather than platinum-based chemotherapy, as this combination improved overall survival (OS) with an acceptable toxicity profile in a phase III trial. </p><p class="headingAnchor" id="H526679001"><span class="h4">Dosing</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="126407" href="/d/drug information/126407.html" rel="external">Enfortumab vedotin</a> is an antibody targeting the cell adhesion molecule nectin-4 linked to a microtubule inhibitor conjugate (monomethyl auristatin E). Enfortumab vedotin is administered intravenously (IV) at 1.25 mg/kg (up to a maximum of 125 mg for patients ≥100 kg) on days 1 and 8 of a 21-day cycle. <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">Pembrolizumab</a> is given IV either at 200 mg every three weeks or 400 mg every six weeks and is administered after enfortumab vedotin when given on the same day. Enfortumab vedotin is typically administered in combination with pembrolizumab for a median of seven to nine cycles as tolerated, mainly to avoid the risk of cumulative neurotoxicity. Pembrolizumab is then continued as monotherapy for up to 24 months, or until disease progression or unacceptable toxicity during that period [<a href="#rid15">15-17</a>].</p><p class="headingAnchor" id="H4034672759"><span class="h4">Efficacy</span><span class="headingEndMark"> — </span>In a phase III trial (EV-302), 886 patients with previously untreated, locally advanced unresectable or metastatic UC who were eligible for platinum-based chemotherapy (ie, <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> or <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a>) were randomly assigned to either <a class="drug drug_general" data-topicid="126407" href="/d/drug information/126407.html" rel="external">enfortumab vedotin</a> plus <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> or chemotherapy (<a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> plus either cisplatin or carboplatin) [<a href="#rid17">17</a>]. Among the patients who received chemotherapy, more than half received subsequent immunotherapy, either as maintenance <a class="drug drug_general" data-topicid="112481" href="/d/drug information/112481.html" rel="external">avelumab</a> (30 percent), upon disease progression (26 percent), or for other reasons (4 percent).</p><p>In preliminary results, relative to chemotherapy, <a class="drug drug_general" data-topicid="126407" href="/d/drug information/126407.html" rel="external">enfortumab vedotin</a> demonstrated the following [<a href="#rid17">17</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Entire study population</strong> – Improved OS (median 31 versus 16 months, hazard ratio [HR] 0.47, 95% CI 0.38-0.58) and progression-free survival (PFS; median 13 versus 6 months, HR 0.45, 95% CI 0.38-0.54), as well as higher objective (68 versus 44 percent) and complete (29 versus 13 percent) response rates.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cisplatin-eligible patients</strong> – Data for cisplatin-eligible patients are discussed separately. (See <a class="local">'Enfortumab vedotin plus pembrolizumab (cisplatin-eligible)'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cisplatin-ineligible patients</strong> – Data for cisplatin-ineligible patients are discussed separately. (See <a class="local">'Enfortumab vedotin plus pembrolizumab (cisplatin-ineligible)'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other subgroups</strong> – OS and PFS benefits were also seen across all clinically relevant subgroups including age (older versus younger than 65 years), performance status (ECOG score of 0 versus 1 to 2  (<a class="graphic graphic_table graphicRef72901" href="/d/graphic/72901.html" rel="external">table 3</a>)), upper versus lower tract disease, presence versus absence of liver metastases, and level of programmed cell death ligand 1 (PD-L1) expression.</p><p></p><p class="headingAnchor" id="H1625346013"><span class="h4">Toxicity</span><span class="headingEndMark"> — </span>Some common toxicity considerations for <a class="drug drug_general" data-topicid="126407" href="/d/drug information/126407.html" rel="external">enfortumab vedotin</a> plus <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> are as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Peripheral neuropathy</strong> – Patients should be monitored for peripheral neuropathy, as <a class="drug drug_general" data-topicid="126407" href="/d/drug information/126407.html" rel="external">enfortumab vedotin</a> is associated with cumulative neurotoxicity. (See  <a class="medical medical_review" href="/d/html/2825.html" rel="external">"Neurologic complications of cancer treatment with molecularly targeted and biologic agents", section on 'Enfortumab vedotin'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ocular, pulmonary, and cutaneous toxicities</strong> – <a class="drug drug_general" data-topicid="126407" href="/d/drug information/126407.html" rel="external">Enfortumab vedotin</a> has been associated with ocular toxicities, pneumonitis, and in rare cases, severe life-threatening cutaneous skin reactions. Patients on should be closely monitored and treated for these toxicities, which is discussed separately. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Ocular toxicity</strong> (see  <a class="medical medical_review" href="/d/html/96203.html" rel="external">"Ocular side effects of systemically administered chemotherapy", section on 'Antibody-drug conjugates'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pulmonary toxicity</strong> (see  <a class="medical medical_review" href="/d/html/4336.html" rel="external">"Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents", section on 'Other antibody-drug conjugates'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cutaneous toxicity, including severe cutaneous reactions</strong> (see  <a class="medical medical_review" href="/d/html/2088.html" rel="external">"Cutaneous adverse events of molecularly targeted therapy and other biologic agents used for cancer therapy", section on 'Antibody-drug conjugates'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hyperglycemia</strong> – Although <a class="drug drug_general" data-topicid="126407" href="/d/drug information/126407.html" rel="external">enfortumab vedotin</a> plus <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> can cause hyperglycemia, this combination may be safely used in patients with diabetes mellitus that is well controlled on therapy. Baseline HbA1c measurement is recommended. (See  <a class="medical medical_review" href="/d/html/1812.html" rel="external">"Clinical presentation, diagnosis, and initial evaluation of diabetes mellitus in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunotherapy toxicity</strong> – Diagnosis and management of immune-related adverse events are discussed separately. (See  <a class="medical medical_review" href="/d/html/96368.html" rel="external">"Toxicities associated with immune checkpoint inhibitors"</a>.)</p><p></p><p>In a phase III trial (EV-302), grade ≥3 toxicity was lower with <a class="drug drug_general" data-topicid="126407" href="/d/drug information/126407.html" rel="external">enfortumab vedotin</a> plus <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> versus platinum-based chemotherapy (56 versus 70 percent), with no new toxicity profiles noted. Common grade ≥3 toxicities for enfortumab vedotin plus pembrolizumab were maculopapular rash (8 percent), hyperglycemia, and neutropenia (5 percent each), as well as peripheral neuropathy and diarrhea (4 percent). By contrast, common grade ≥3 toxicities for chemotherapy were mainly hematologic, including anemia (31 percent), neutropenia (30 percent), and thrombocytopenia (18 percent).</p><p class="headingAnchor" id="H468944711"><span class="h3">Cisplatin-eligible</span><span class="headingEndMark"> — </span>For patients with advanced or metastatic UC who are eligible for cisplatin-based regimens, <a class="drug drug_general" data-topicid="126407" href="/d/drug information/126407.html" rel="external">enfortumab vedotin</a> plus <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> is a preferred option for initial therapy as this combination improves OS with an acceptable toxicity profile.</p><p>For patients who are not eligible for, decline, or lack access to this combination, alternative options for initial therapy include <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> and <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, <strong>or</strong> cisplatin-based chemotherapy followed by maintenance <a class="drug drug_general" data-topicid="112481" href="/d/drug information/112481.html" rel="external">avelumab</a> for patients without disease progression. Either approach is reasonable as the optimal sequencing of chemotherapy and immunotherapy for initial therapy (concurrent versus sequential) is not established. (See <a class="local">'Nivolumab plus gemcitabine plus cisplatin'</a> below and <a class="local">'Cisplatin-based chemotherapy'</a> below.)</p><p class="headingAnchor" id="H2987275207"><span class="h4">Enfortumab vedotin plus pembrolizumab (cisplatin-eligible)</span><span class="headingEndMark"> — </span>In a phase III trial (EV-302) of 886 patients with advanced or metastatic UC who were eligible for platinum-based chemotherapy, <a class="drug drug_general" data-topicid="126407" href="/d/drug information/126407.html" rel="external">enfortumab vedotin</a> plus <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> was compared to <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> or <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> [<a href="#rid17">17</a>]. Approximately one-third of patients in the control arm received maintenance immunotherapy. In preliminary results, among the 478 patients eligible for cisplatin, enfortumab vedotin plus pembrolizumab improved OS (median 32 versus 18 months, HR 0.53, 95% CI 0.39-0.72) and PFS (HR 0.48, 95% CI 0.38-0.62) relative to platinum-based chemotherapy.</p><p>Further details on this study, including results for the entire study population and toxicities, are discussed separately. (See <a class="local">'Enfortumab vedotin plus pembrolizumab'</a> above.)</p><p class="headingAnchor" id="H3951723165"><span class="h4">Nivolumab plus gemcitabine plus cisplatin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">Nivolumab</a> plus <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> is one appropriate option for initial therapy in cisplatin-eligible patients with advanced or metastatic UC who are ineligible for, decline, or lack access to <a class="drug drug_general" data-topicid="126407" href="/d/drug information/126407.html" rel="external">enfortumab vedotin</a> plus <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>. In a phase III trial, the addition of nivolumab to gemcitabine plus <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> improved OS but increased toxicity [<a href="#rid18">18</a>].</p><p>In an open-label phase III trial (CheckMate-901), 608 cisplatin-eligible patients with previously untreated unresectable or metastatic urothelial carcinoma were randomly assigned to either six cycles of <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> and <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> every three weeks followed by maintenance nivolumab, or six cycles of gemcitabine plus cisplatin every three weeks [<a href="#rid18">18</a>]. Patients assigned to nivolumab plus chemotherapy received up to six cycles of gemcitabine and cisplatin administered concurrently with nivolumab at a dose of 360 mg IV every three weeks followed by nivolumab monotherapy at a dose of 480 mg IV every four weeks up to two years, or until disease progression or unacceptable toxicity during that period.</p><p>Patients were permitted prior intravesical therapy (completed more than four weeks before) or prior neoadjuvant therapy, radiation therapy, or adjuvant platinum-based chemotherapy for locally advanced disease, with recurrence one year or more after treatment completion. Patients who discontinued <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> could be switched to <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> for the remainder of the chemotherapy cycles (up to six cycles total).</p><p>At median follow-up of 34 months the addition of <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> improved OS (median 22 versus 19 months, HR 0.72, 95% CI 0.59-0.88) and PFS (median 7.9 versus 7.6 months, HR 0.72, 95% CI 0.59-0.88). Combination therapy also increased the duration of complete response (median 37 versus 13 months) and improved the objective (58 versus 43 percent) and complete response rates (22 versus 12 percent).</p><p>Grade ≥3 toxicity rates were higher with combination therapy versus <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> (77 versus 68 percent). Health-related quality of life after four months of therapy was similar between the two groups.</p><p>It is unclear whether the concurrent administration of immunotherapy with chemotherapy is superior to sequential administration of these agents, and further data are necessary. A subgroup of patients treated with <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> did receive sequential maintenance immunotherapy, but the efficacy of this approach compared with concurrent administration of <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus gemcitabine and cisplatin was not reported. Further details on the sequential administration of chemotherapy and maintenance immunotherapy are discussed below. (See <a class="local">'Cisplatin-based chemotherapy'</a> below and <a class="local">'Maintenance therapy'</a> below.)</p><p class="headingAnchor" id="H514200482"><span class="h4">Cisplatin-based chemotherapy</span><span class="headingEndMark"> — </span>Cisplatin-based chemotherapy is one appropriate option for cisplatin-eligible patients with advanced or metastatic UC who are ineligible, decline, or lack access to <a class="drug drug_general" data-topicid="126407" href="/d/drug information/126407.html" rel="external">enfortumab vedotin</a> plus <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>. Patients who do not progress on cisplatin-based chemotherapy are treated with maintenance <a class="drug drug_general" data-topicid="112481" href="/d/drug information/112481.html" rel="external">avelumab</a>. (See <a class="local">'Maintenance therapy'</a> below.)</p><p>The choice between available cisplatin-based regimens is individualized based on patient and provider preferences. Options are as follows:</p><p class="headingAnchor" id="H1495807279"><span class="h5">MVAC</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">Methotrexate</a>, <a class="drug drug_general" data-topicid="10044" href="/d/drug information/10044.html" rel="external">vinblastine</a>, <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, and <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> (MVAC)  (<a class="graphic graphic_table graphicRef64950" href="/d/graphic/64950.html" rel="external">table 5</a>) is an option for the initial therapy of patients with advanced or metastatic UC who are cisplatin-eligible, as this approach improved OS compared with single-agent cisplatin [<a href="#rid5">5,19</a>]. MVAC is administered as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>MVAC</strong> – <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">Methotrexate</a> (30 mg/m<sup>2</sup> on days 1, 15, and 22), <a class="drug drug_general" data-topicid="10044" href="/d/drug information/10044.html" rel="external">vinblastine</a> (3 mg/m<sup>2</sup> on days 2, 15, and 22), <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a> (30 mg/m<sup>2</sup> on day 2), and <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> (70 mg/m<sup>2</sup> on day 2), repeated every 28 days for six cycles  (<a class="graphic graphic_table graphicRef64950" href="/d/graphic/64950.html" rel="external">table 5</a>).</p><p></p><p>The efficacy of this regimen was demonstrated in a multicenter trial of 269 patients with advanced urothelial carcinoma who were randomly assigned to treatment with either MVAC or single-agent <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> [<a href="#rid5">5</a>]. Compared with cisplatin, MVAC resulted in:</p><p class="bulletIndent1"><span class="glyph">●</span>A significant improvement in the overall response rate (ORR; 39 versus 12 percent)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A significant increase in median PFS (10 versus 4 months)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A significant improvement in median OS (13 versus 8 months)</p><p></p><p>Toxicity is a major concern with MVAC therapy, particularly since many patients with bladder cancer are older adults or have multiple comorbidities. Myelosuppression, neutropenic fever, sepsis, mucositis, and nausea and vomiting are common. As an example, 54 percent of patients in one earlier series were hospitalized due to toxicity [<a href="#rid20">20</a>]. Furthermore, toxicity-related deaths have been reported in most trials evaluating MVAC for advanced urothelial cancer [<a href="#rid5">5,21</a>]. The use of dose-dense MVAC (which incorporates hematopoietic growth factor support) may ameliorate some of these toxicities, especially myelosuppression and mucositis [<a href="#rid22">22,23</a>].</p><p class="headingAnchor" id="H2539155969"><span class="h5">Dose-dense MVAC</span><span class="headingEndMark"> — </span>Dose-dense MVAC is another option for initial therapy of patients with advanced or metastatic UC of the bladder who are cisplatin-eligible. </p><p>Dose-dense MVAC is administered as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose-dense MVAC</strong> – <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">Methotrexate</a> (30 mg/m<sup>2</sup> on day 1), <a class="drug drug_general" data-topicid="10044" href="/d/drug information/10044.html" rel="external">vinblastine</a> (3 mg/m<sup>2</sup> on day 2), <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a> (30 mg/m<sup>2</sup> on day 2), and <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> (70 mg/m<sup>2 </sup>on day 2) with granulocyte-colony stimulating factor (G-CSF) support, repeated every 14 days for six cycles  (<a class="graphic graphic_table graphicRef111814" href="/d/graphic/111814.html" rel="external">table 6</a>).</p><p></p><p>Increasing the dose intensity of MVAC by administering treatment every two weeks with G-CSF support has also been evaluated in an effort to improve long-term survival. In a randomized phase III trial, although dose-dense MVAC failed to improve OS over classic MVAC, it improved PFS and reduced toxicity [<a href="#rid24">24,25</a>]. There is no consensus, and thus, both standard MVAC and dose-dense MVAC  (<a class="graphic graphic_table graphicRef111814" href="/d/graphic/111814.html" rel="external">table 6</a>) are used frequently in clinical practice.</p><p>In a phase III trial (European Organisation for Research and Treatment of Cancer [EORTC] 30924), 263 patients with advanced or metastatic urothelial cancer were randomly assigned to either dose-dense MVAC (every two-week cycle with growth factor support) or classic MVAC (every four-week cycle) [<a href="#rid24">24,25</a>]. Patients treated with dose-dense MVAC received a median of six cycles and a treatment duration of 12 weeks, whereas those treated with classic MVAC received a median of four treatment cycles and a treatment duration of 21 weeks. </p><p>At median follow-up of 38 months, relative to classic MVAC, results for dose-dense MVAC were as follows [<a href="#rid24">24</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Improved PFS (median 9.1 versus 8.2 months, two-year PFS 25 versus 12 percent, HR 0.75, 95% CI 0.58-0.98). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Higher complete response rates (21 versus 9 percent). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similar OS (median 15.5 versus 14.1 months, two-year OS 35 versus 25 percent, HR 0.80, 95% CI 0.60-1.06). In subsequent follow-up, five-year OS was higher with dose-dense MVAC than classic MVAC, although the difference was not statistically significant (five-year OS 22 versus 14 percent) [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A more favorable toxicity profile, including lower rates of grade ≥3 leukopenia (20 versus 62 percent) and mucositis (10 versus 17 percent), as well as neutropenic fever of any grade (10 versus 26 percent). These findings were likely attributed to the use of growth factor support. </p><p></p><p class="headingAnchor" id="H933456754"><span class="h5">Gemcitabine plus cisplatin</span><span class="headingEndMark"> — </span>The combination of <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> (GC) is another option for initial therapy of patients with advanced or metastatic UC of the bladder who are cisplatin-eligible. GC has similar efficacy and less toxicity compared with MVAC  (<a class="graphic graphic_table graphicRef64950" href="/d/graphic/64950.html" rel="external">table 5</a>). This regimen is administered as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>GC</strong> – <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">Gemcitabine</a> (1000 mg/m<sup>2</sup> on days 1, 8, 15) plus <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> (70 mg/m<sup>2</sup> on day 2), repeated every 28 days for a maximum of six cycles  (<a class="graphic graphic_table graphicRef53016" href="/d/graphic/53016.html" rel="external">table 7</a>). An alternative regimen consists of gemcitabine (1200 mg/m<sup>2</sup> on days 1 and 8) and cisplatin (75 mg/m<sup>2</sup> on day 2), repeated every 21 days for a median of six cycles.</p><p></p><p>In a phase III trial, 405 patients with metastatic UC were randomly assigned to initial therapy with up to six cycles of either GC or classic MVAC [<a href="#rid26">26,27</a>]. At median follow-up of 19 months, compared with MVAC, GC resulted in:</p><p class="bulletIndent1"><span class="glyph">●</span>Similar ORR (49 versus 46 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similar time to disease progression (seven months in each arm, HR 1.05, 95% CI 0.85-1.30).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similar OS (14 versus 15 months, HR 1.04 95% CI 0.82-1.32). At five years, there was also a similar five-year survival rate (13 and 15 percent) [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similar quality of life, though patients experienced less weight loss, a better performance status, and less fatigue.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Less grade ≥3 toxicity, including neutropenia (71 versus 82 percent), neutropenic sepsis (2 versus 14 percent), and mucositis (1 versus 22 percent) [<a href="#rid26">26,27</a>].</p><p></p><p>Alternate dosing schedules with the GC regimen have used a three-week instead of four-week schedule [<a href="#rid28">28-30</a>]. Although these different GC schedules have not been compared in randomized phase III trials, the results appear to be similar. Of note, one trial comparing dose-dense GC versus dose-dense MVAC demonstrated no apparent benefit to dose intensification [<a href="#rid31">31</a>].</p><p class="headingAnchor" id="H973607999"><span class="h5">PGC (paclitaxel plus GC)</span><span class="headingEndMark"> — </span>The triplet combination of <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a>, <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a>, and <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> (PGC)  (<a class="graphic graphic_table graphicRef140871" href="/d/graphic/140871.html" rel="external">table 8</a>) is another option for patients with metastatic UC of the bladder who are cisplatin-eligible. PGC is administered as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>PGC</strong> – <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">Paclitaxel</a> (80 mg/m<sup>2</sup> before <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> and <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> on days 1 and 8), gemcitabine (1000 mg/m<sup>2</sup> on days 1 and 8), and cisplatin (70 mg/m<sup>2</sup> on day 1), repeated every 21 days for a maximum of six cycles  (<a class="graphic graphic_table graphicRef140871" href="/d/graphic/140871.html" rel="external">table 8</a>).</p><p></p><p>The efficacy of this regimen was demonstrated in the EORTC study 30987, which enrolled 626 patients with advanced UC (81 percent with primary bladder cancer) and randomly assigned them to treatment with GC or PGC for a maximum of six cycles. At median follow-up of 4.6 years, compared with GC, PGC resulted in the following [<a href="#rid32">32</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>An increase in the ORR (56 versus 44 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A trend towards an improvement in PFS (median 8.3 versus 7.6 months, HR for progression 0.87, 95% CI 0.74-1.03).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A trend towards longer OS (median 16 versus 13 months, HR for death 0.85, 95% CI 0.72-1.02). When the analysis was restricted to patients who met all eligibility criteria (92 percent of the randomized population), PGC was associated with a significant increase in OS (median 16 versus 13 months, HR 0.82, 95% CI 0.68-0.98). In addition, PGC was associated with a significant improvement in OS among patients with primary bladder cancer compared with GC (median 16 versus 12 months, HR 0.80, 95% CI 0.66-0.97).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An increased incidence of serious (grade 3/4) toxicity, including neutropenia (65 versus 51 percent), fatigue (15 versus 11 percent), and infections (18 versus 14 percent), but a lower incidence of serious (grade 3/4) thrombocytopenia (35 versus 52 percent).</p><p></p><p class="headingAnchor" id="H1857848470"><span class="h3">Cisplatin-ineligible</span><span class="headingEndMark"> — </span>For patients who are ineligible for cisplatin-based therapy, we recommend initial treatment with <a class="drug drug_general" data-topicid="126407" href="/d/drug information/126407.html" rel="external">enfortumab vedotin</a> plus <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> rather than platinum-based chemotherapy, as this combination has high objective response rates and improves OS with an acceptable toxicity profile. (See <a class="local">'Enfortumab vedotin plus pembrolizumab (cisplatin-ineligible)'</a> below.)</p><p>For cisplatin-ineligible patients who are ineligible for, decline, or lack access to this combination, <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> is an appropriate alternative. (See <a class="local">'Gemcitabine plus carboplatin'</a> below.)</p><p class="headingAnchor" id="H1266345680"><span class="h4">Enfortumab vedotin plus pembrolizumab (cisplatin-ineligible)</span><span class="headingEndMark"> — </span>For cisplatin-ineligible patients with advanced or metastatic UC, the efficacy of <a class="drug drug_general" data-topicid="126407" href="/d/drug information/126407.html" rel="external">enfortumab vedotin</a> plus <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> was initially demonstrated in early phase clinical trials, including a phase Ib/II trial (EV-103/KEYNOTE 869 Cohort A), which demonstrated high ORR response rates (65 percent or more) [<a href="#rid33">33,34</a>].</p><p>The clinical benefit of this combination was subsequently confirmed in randomized phase II and III trials [<a href="#rid17">17,34</a>]. Data are as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>In a randomized phase II trial (EV-103/ KEYNOTE-869 Cohort K), 149 patients with previously untreated, locally advanced or metastatic UC who were ineligible for cisplatin-based regimens were randomly assigned to the combination of <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> plus <a class="drug drug_general" data-topicid="126407" href="/d/drug information/126407.html" rel="external">enfortumab vedotin</a> (76 patients) or enfortumab vedotin alone (73 patients) [<a href="#rid34">34</a>]. At median follow-up of approximately 15 months, relative to enfortumab vedotin alone, the combination resulted in the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A non-statistically significant trend towards an improved objective response rate (65 percent versus 45 percent). Complete response rates were also higher for the combination (11 versus 4 percent).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A non-statistically significant trend towards longer one-year PFS (55 versus 36 percent) and OS (81 versus 70 percent).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The median duration of response for the combination was not reached versus 13 months for <a class="drug drug_general" data-topicid="126407" href="/d/drug information/126407.html" rel="external">enfortumab vedotin</a> alone.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The median time to response was similar for both treatment arms (two months each).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For the 121 patients from both Cohort A and K treated with the combination, the objective and complete response rates were 68 and 12 percent, respectively [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A subsequent randomized phase III trial (EV-302) comparing <a class="drug drug_general" data-topicid="126407" href="/d/drug information/126407.html" rel="external">enfortumab vedotin</a> plus <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> to <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> or <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> including a subgroup of 408 patients who were cisplatin-ineligible [<a href="#rid17">17</a>]. In preliminary results, among this subgroup, enfortumab vedotin improved both OS (HR 0.43, 95% CI 0.31-0.59) and PFS (HR 0.43, 95% CI 0.33-0.55) relative to chemotherapy. Further data on the entire population and other subgroups are discussed separately. (See <a class="local">'Enfortumab vedotin plus pembrolizumab (cisplatin-eligible)'</a> above.)</p><p></p><p>The US Food and Drug Administration (FDA) granted accelerated approval for the combination of <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> plus <a class="drug drug_general" data-topicid="126407" href="/d/drug information/126407.html" rel="external">enfortumab vedotin</a> for the treatment of adult patients with locally advanced or metastatic UC who are not eligible for cisplatin-containing chemotherapy [<a href="#rid15">15,16</a>]. Of note, the United States prescribing label does not define criteria for cisplatin-ineligible patients; our definition is discussed separately. (See <a class="local">'Defining eligibility for systemic therapy'</a> above.)</p><p class="headingAnchor" id="H2528360995"><span class="h4">Gemcitabine plus carboplatin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">Gemcitabine</a> plus <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> is an appropriate alternative for cisplatin-ineligible patients who are not eligible for, decline, or lack access to <a class="drug drug_general" data-topicid="126407" href="/d/drug information/126407.html" rel="external">enfortumab vedotin</a> plus <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>. Examples of patients who may be ineligible to receive enfortumab vedotin plus pembrolizumab include those with pre-existing neuropathy (as enfortumab vedotin is associated with cumulative neurotoxicity), active autoimmune disease, and/or pre-existing cutaneous disorders (as severe life-threatening cutaneous reactions have been reported with enfortumab vedotin). (See <a class="local">'Toxicity'</a> above.)</p><p>Patients who do not progress on <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> are subsequently offered switch maintenance therapy with <a class="drug drug_general" data-topicid="112481" href="/d/drug information/112481.html" rel="external">avelumab</a>. (See <a class="local">'Maintenance therapy'</a> below.)</p><p>In patients with advanced or metastatic UC and impaired kidney function or a poor performance status (ECOG ≥2) who are otherwise candidates for combination chemotherapy, <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> is well tolerated and as effective as more complex carboplatin-based combination regimens, such as MCAVI (<a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, carboplatin, and <a class="drug drug_general" data-topicid="10044" href="/d/drug information/10044.html" rel="external">vinblastine</a>). However, prior to selecting a regimen, it is important to assess the basis for kidney dysfunction. Treating simple and reversible causes, such as urinary obstruction by a primary tumor, may allow the use of cisplatin-based regimens. (See <a class="local">'Nivolumab plus gemcitabine plus cisplatin'</a> above and <a class="local">'Cisplatin-based chemotherapy'</a> above.)</p><p>In a randomized phase II/III trial (EORTC 30986) of 238 chemotherapy-naïve patients with advanced or metastatic UC, impaired kidney function (glomerular filtration rate &lt;60 but &gt;30 mL/minute) and/or a poor performance status (ECOG ≥2) were randomly assigned to either <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> or MCAVI [<a href="#rid35">35</a>]. Compared with MCAVI, treatment with carboplatin plus gemcitabine resulted in:</p><p class="bulletIndent1"><span class="glyph">●</span>Similar OS (median nine versus eight months, HR for death 0.94, 95% CI 0.72-1.22).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similar PFS (six versus four months, HR for progression 1.04, 95% CI 0.80-1.35).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A non-statistically significant increase in ORR (41 versus 30 percent, respectively).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lower grade 3 to 4 toxicity rates (9 versus 21 percent), including neutropenia (52 versus 63 percent) and febrile neutropenia (5 versus 15 percent). However, <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> was associated with a higher rate of serious thrombocytopenia (47 versus 18 percent).</p><p></p><p>Other randomized trials have compared carboplatin-based regimens with cisplatin-based regimens, but interpretation of results were limited by the small number of patients enrolled [<a href="#rid36">36-38</a>]. However, neither efficacy nor toxicity could be evaluated due to the small number of patients enrolled.</p><p class="headingAnchor" id="H1495808211"><span class="h4">Other agents</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gemcitabine</strong><strong> plus taxanes</strong> – Regimens that combine <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> with a taxane (either <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> or <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a>) are active as initial therapy in patients with metastatic UC who are ineligible for cisplatin-based regimens but are still candidates for combination therapy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The combination of <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> plus <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> results in objective response rates of 54 to 70 percent and median survival of 13 to 16 months [<a href="#rid39">39-42</a>]. Toxicity with this combination is primarily hematologic, although severe pulmonary toxicity was reported in five patients treated with paclitaxel on a weekly schedule in one series [<a href="#rid41">41</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Two phase II trials reported outcomes using the combination of <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> plus <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a>, with ORRs of 33 and 52 percent and median OS of 13 and 15 months [<a href="#rid43">43,44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gemcitabine</strong><strong> plus </strong><strong>eribulin</strong> – The combination of <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> with <a class="drug drug_general" data-topicid="16096" href="/d/drug information/16096.html" rel="external">eribulin</a> has been investigated in one early phase II trial, but its role in the treatment of patients with cisplatin-ineligible advanced urothelial cancer is not established [<a href="#rid45">45</a>].</p><p></p><p class="headingAnchor" id="H908109818"><span class="h2">Platinum-ineligible</span><span class="headingEndMark"> — </span>For patients who are ineligible for any platinum-based (ie, <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> or <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a>) chemotherapy, we suggest <a class="drug drug_general" data-topicid="126407" href="/d/drug information/126407.html" rel="external">enfortumab vedotin</a> plus <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> rather than other systemic agents, extrapolating from data in cisplatin-ineligible patients. (See <a class="local">'Enfortumab vedotin plus pembrolizumab (cisplatin-ineligible)'</a> above.)</p><p>Single-agent <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>  (<a class="graphic graphic_table graphicRef127101" href="/d/graphic/127101.html" rel="external">table 9</a>) is an alternative for those who are anticipated to not tolerate this combination therapy or who lack access to <a class="drug drug_general" data-topicid="126407" href="/d/drug information/126407.html" rel="external">enfortumab vedotin</a>  (<a class="graphic graphic_algorithm graphicRef111737" href="/d/graphic/111737.html" rel="external">algorithm 1</a>). (See <a class="local">'Pembrolizumab'</a> below.)</p><p>Patients not eligible for initial therapy with any of the above regimens may be candidates for single-agent chemotherapy and/or best supportive care. (See <a class="local">'Single-agent chemotherapy'</a> below.)</p><p class="headingAnchor" id="H3425981559"><span class="h3">Enfortumab vedotin plus pembrolizumab</span><span class="headingEndMark"> — </span>We recommend <a class="drug drug_general" data-topicid="126407" href="/d/drug information/126407.html" rel="external">enfortumab vedotin</a> plus <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> for patients who are ineligible for any platinum-based combination chemotherapy regimen. The use of this combination in this population is extrapolated from data in patients who are ineligible for cisplatin-based therapy, which demonstrated high response rates in non-randomized trials as well as an OS benefit relative to platinum-based chemotherapy in randomized trials. Further details are discussed separately. (See <a class="local">'Enfortumab vedotin plus pembrolizumab (cisplatin-ineligible)'</a> above.)</p><p class="headingAnchor" id="H456448324"><span class="h3">Pembrolizumab</span><span class="headingEndMark"> — </span>In the phase II KEYNOTE-052 study, 370 patients with advanced UC who were not eligible for a cisplatin-based regimen received initial therapy with <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> at 200 mg every three weeks for up to two years  (<a class="graphic graphic_table graphicRef127101" href="/d/graphic/127101.html" rel="external">table 9</a>) [<a href="#rid46">46-48</a>]. The average age of the study population was 74 years, and 29 percent of patients were aged ≥80 years. Liver metastases were present in 21 percent, and 42 percent were performance status 2; 50 percent of patients were included because of kidney impairment.</p><p>At a median follow-up of almost five years (56 months), the ORR, the primary endpoint of the study, was 29 percent for the entire cohort, including complete and partial response rates of 9 and 20 percent, respectively [<a href="#rid48">48</a>]. The median duration of response was 33 months. Response rates were consistent across all major subgroups. The ORR was higher in patients with combined positive score (CPS) &gt;10 compared with those with CPS ≤10 (47 versus 21 percent). Overall, the median OS was 11 months and four-year OS was 19 percent.</p><p>Based on these data, the US FDA approved single-agent <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> as initial therapy in patients who are not eligible for any platinum-containing chemotherapy [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H2587641777"><span class="h3">Single-agent chemotherapy</span><span class="headingEndMark"> — </span>Many chemotherapy drugs are active as single agents in patients with advanced or metastatic UC, either as initial or later lines of therapy. However, these agents do not improve OS and responses are generally not durable. The choice between agents should be based on clinical factors, such as the patient's performance status, and the patient's values and preferences. Options include platinum agents (<a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a>), <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a>, vinca alkaloids (<a class="drug drug_general" data-topicid="10044" href="/d/drug information/10044.html" rel="external">vinblastine</a>, vinflunine), anthracyclines (<a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="8663" href="/d/drug information/8663.html" rel="external">epirubicin</a>), <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, taxanes (<a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a>, <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a>, and nanoparticle albumin-bound paclitaxel<strong> </strong>[<a class="drug drug_general" data-topicid="10159" href="/d/drug information/10159.html" rel="external">nabpaclitaxel</a>]), and <a class="drug drug_general" data-topicid="8552" href="/d/drug information/8552.html" rel="external">ifosfamide</a> [<a href="#rid49">49-58</a>]. </p><p class="headingAnchor" id="H3080699837"><span class="h2">Other agents</span><span class="headingEndMark"> — </span>Other regimens either are not used or remain investigational for initial treatment of advanced or metastatic UC.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nivolumab</strong><strong> plus </strong><strong>ipilimumab</strong> – We do not offer initial treatment with <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>. In preliminary results from a phase III trial (CheckMate-901, part 2), nivolumab plus ipilimumab failed to improve OS over <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> or <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> [<a href="#rid59">59</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pembrolizumab</strong><strong> plus platinum-based chemotherapy</strong> – We do not offer initial treatment with <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> plus platinum-based chemotherapy. In a phase III trial (KEYNOTE-361) of 1010 patients with treatment-naïve unresectable or metastatic urothelial carcinoma, the addition of pembrolizumab to chemotherapy did not improve OS or PFS [<a href="#rid60">60</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Atezolizumab</strong> – We do not offer initial therapy with <a class="drug drug_general" data-topicid="108314" href="/d/drug information/108314.html" rel="external">atezolizumab</a>, either as monotherapy or in combination with cisplatin-based chemotherapy, in patients with metastatic UC.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="108314" href="/d/drug information/108314.html" rel="external">Atezolizumab</a> was initially granted accelerated approval by the US FDA, based on clinical activity in a single-arm phase II trial [<a href="#rid61">61</a>]. However, in a randomized phase III trial (IMvigor130), the addition of atezolizumab to <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> plus platinum-based chemotherapy as initial therapy improved PFS but not OS [<a href="#rid62">62,63</a>]. Additionally, atezolizumab monotherapy did not improve OS over platinum-based chemotherapy [<a href="#rid64">64</a>]. Based on these data, regulatory approval for atezolizumab was voluntarily withdrawn in the United States for patients with advanced or metastatic UC who are ineligible for either cisplatin-containing chemotherapy and whose tumors express PD-L1, or those who are ineligible for any platinum-containing chemotherapy [<a href="#rid65">65</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Avelumab</strong> – The use of <a class="drug drug_general" data-topicid="112481" href="/d/drug information/112481.html" rel="external">avelumab</a> as initial therapy in metastatic UC remains investigational. In a single-arm phase II trial (ARIES), avelumab demonstrated clinical activity in patients with PD-L1 positive metastatic UC who are <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> ineligible [<a href="#rid66">66</a>]. At median follow-up of 10 months, objective and complete response rates were 24 and 9 percent, respectively.</p><p></p><p class="headingAnchor" id="H1743369083"><span class="h1">MAINTENANCE THERAPY</span></p><p class="headingAnchor" id="H122817695"><span class="h2">Avelumab</span><span class="headingEndMark"> — </span>For patients with advanced or metastatic urothelial carcinoma (UC) who do not progress (ie, achieve an objective response or stable disease) following platinum-based chemotherapy and are eligible to receive immune checkpoint inhibitors, we suggest maintenance <a class="drug drug_general" data-topicid="112481" href="/d/drug information/112481.html" rel="external">avelumab</a>, rather than best supportive care (BSC) alone, as this approach improved overall survival (OS) and progression-free survival (PFS) in a phase III trial [<a href="#rid67">67,68</a>]. Although this study only evaluated maintenance avelumab in patients who received <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> plus platinum-based chemotherapy, we also offer this approach to those who have not progressed on other platinum-based chemotherapy regimens, extrapolating from the results of this trial.</p><p>For those treated with a platinum-based chemotherapy who are ineligible for maintenance immunotherapy, we offer observation with BSC rather than maintenance therapy with other systemic agents  (<a class="graphic graphic_algorithm graphicRef111737" href="/d/graphic/111737.html" rel="external">algorithm 1</a>).</p><p>Maintenance <a class="drug drug_general" data-topicid="112481" href="/d/drug information/112481.html" rel="external">avelumab</a> is administered at a flat dose of 800 mg every two weeks until disease progression or unacceptable toxicity after 4 to 10 weeks of completing therapy. We initiate maintenance avelumab after patients have completed four to six cycles of chemotherapy and have confirmed response or stable disease on radiographic imaging.</p><p>In a randomized phase III trial (JAVELIN Bladder 100), 700 patients with locally advanced unresectable or metastatic urothelial bladder cancer who experienced either an objective response (ie, complete or partial response) or stable disease after four to six cycles of <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> plus platinum-based chemotherapy were randomly assigned to either maintenance <a class="drug drug_general" data-topicid="112481" href="/d/drug information/112481.html" rel="external">avelumab</a> and BSC or BSC alone [<a href="#rid67">67</a>]. The study included a subset of 358 patients (51 percent) with programmed cell death ligand 1 (PD-L1) positive tumors identified using a specific assay [<a href="#rid69">69,70</a>].</p><p>At median follow-up of approximately 39 months, in the entire study population, the addition of <a class="drug drug_general" data-topicid="112481" href="/d/drug information/112481.html" rel="external">avelumab</a> to BSC improved OS and PFS (three-year OS 36 versus 30 percent, median 24 versus 15 months, hazard ratio [HR] 0.76, 95% CI 0.63-0.91; three-year PFS 16 versus 5 percent, median 6 versus 2 months, HR 0.54, 95% CI 0.46-0.64) [<a href="#rid68">68</a>]. For those with PD-L1 positive tumors, avelumab also improved OS (HR 0.69, 95% CI 0.53-0.91) and PFS (HR 0.46, 95% CI 0.36-0.59). OS benefit from maintenance avelumab was still maintained despite a high proportion of patients treated with BSC receiving subsequent therapy (72 percent), most commonly programmed cell death protein 1 (PD-1) or PD-L1 inhibitors (53 percent).</p><p>Maintenance <a class="drug drug_general" data-topicid="112481" href="/d/drug information/112481.html" rel="external">avelumab</a> also improved survival regardless of the platinum-based chemotherapy regimen received, including <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> and gemcitabine plus <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> [<a href="#rid71">71</a>]. Preliminary data also suggest that avelumab has an OS benefit independent of the number of chemotherapy cycles received (between four and six cycles) [<a href="#rid72">72</a>].</p><p>Long-term treatment with maintenance <a class="drug drug_general" data-topicid="112481" href="/d/drug information/112481.html" rel="external">avelumab</a> was well tolerated and maintained quality of life [<a href="#rid73">73</a>]. In all patients, grade ≥3 toxicity rates were higher for maintenance avelumab than BSC (48 versus 25 percent), with no new toxicity signals identified; the most common grade ≥3 toxicities for those treated with avelumab for ≥12 months included urinary tract infection (3 percent each), diarrhea (&lt;1 percent), and arthralgias (&lt;1 percent) [<a href="#rid68">68</a>]. The grade ≥3 immune-related adverse event rate in those treated with avelumab was 7 percent. Two patients died from sepsis and ischemic stroke.</p><p>Based on these data, the US Food and Drug Administration (FDA) approved <a class="drug drug_general" data-topicid="112481" href="/d/drug information/112481.html" rel="external">avelumab</a> for maintenance therapy in patients with locally advanced or metastatic UC that has not progressed on initial platinum-based chemotherapy [<a href="#rid74">74</a>].</p><p class="headingAnchor" id="H749236027"><span class="h2">Other agents</span><span class="headingEndMark"> — </span>The role of other agents, such as <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> [<a href="#rid75">75</a>], vinflunine [<a href="#rid57">57,76</a>], and <a class="drug drug_general" data-topicid="111396" href="/d/drug information/111396.html" rel="external">rucaparib</a> for tumors with a DNA repair deficiency phenotype [<a href="#rid77">77</a>], is not established in the maintenance setting, as they have demonstrated PFS but not OS benefit in randomized phase II trials.</p><p class="headingAnchor" id="H2663341426"><span class="h1">SECOND-LINE THERAPY</span></p><p class="headingAnchor" id="H3826997674"><span class="h2">Prior platinum, no prior immunotherapy</span><span class="headingEndMark"> — </span>For patients with advanced or metastatic urothelial carcinoma (UC) who progress on a platinum-based regimen and have had not received prior treatment with immunotherapy, we recommend immune checkpoint inhibitors rather than chemotherapy. While we prefer <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>  (<a class="graphic graphic_table graphicRef127101" href="/d/graphic/127101.html" rel="external">table 9</a>), which improved overall survival (OS) in a randomized trial, other options include <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a>  (<a class="graphic graphic_table graphicRef127100" href="/d/graphic/127100.html" rel="external">table 10</a>), and <a class="drug drug_general" data-topicid="112481" href="/d/drug information/112481.html" rel="external">avelumab</a>.</p><p class="headingAnchor" id="H4106201560"><span class="h3">Pembrolizumab</span><span class="headingEndMark"> — </span>In patients with advanced or metastatic UC who progress on platinum-based chemotherapy, <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>  (<a class="graphic graphic_table graphicRef127101" href="/d/graphic/127101.html" rel="external">table 9</a>) prolongs OS with less toxicity and better quality of life compared with further lines of chemotherapy.</p><p>In a phase III trial (KEYNOTE-045), 542 patients with locally advanced or metastatic UC who recurred or progressed on a platinum-containing regimen were randomly assigned to <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> (200 mg every three weeks for 24 months) or investigator's choice of chemotherapy (<a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a>, <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a>, or vinflunine) [<a href="#rid48">48,78-80</a>].</p><p>At median follow-up of approximately 28 months, relative to chemotherapy, <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> improved OS (median OS 10 versus 7 months; one-year OS 44 versus 30 percent; two-year OS 27 versus 14 percent; hazard ratio [HR] 0.70, 95% CI 0.57-0.85) and objective response rates (21 versus 11 percent) [<a href="#rid78">78,80</a>]. Median duration of response was not reached for pembrolizumab versus four months for chemotherapy [<a href="#rid80">80</a>]. Progression-free survival (PFS) was similar between the two treatment arms (median PFS two versus three months, HR 0.96, 95% CI 0.79-1.16).</p><p>Grade ≥3 treatment-related adverse events with <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> were less frequent compared with chemotherapy (17 versus 50 percent) with longer time to health-related quality of life deterioration (3.5 versus 2.3 months, HR 0.72) [<a href="#rid79">79</a>]. Similar outcomes were demonstrated with longer follow-up of this study [<a href="#rid48">48</a>].</p><p><a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">Pembrolizumab</a> is approved by the US FDA for patients with locally advanced or metastatic UC who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H1031998227"><span class="h3">Nivolumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">Nivolumab</a>  (<a class="graphic graphic_table graphicRef127100" href="/d/graphic/127100.html" rel="external">table 10</a>) is an option for patients with advanced or metastatic UC who progress on platinum-based chemotherapy, with objective response rates up to 26 percent [<a href="#rid81">81,82</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Single-agent </strong><a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> – In phase I and II studies, nivolumab has had significant activity in patients who have progressed after previous platinum-based therapy for metastatic UC [<a href="#rid81">81,83</a>].</p><p></p><p class="bulletIndent1">In a phase II trial, 270 patients were treated with <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> (3 mg per kilogram every two weeks) [<a href="#rid81">81</a>]. The objective response rate was 20 percent, with responses at all levels of programmed cell death ligand 1 (PD-L1) expression. At seven months of follow-up, OS for the entire cohort was 9 months; for those with PD-L1 expression &lt;1 and ≥1 percent, median OS was 6 and 11 months, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>What is the role of </strong><a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a><strong> plus </strong><a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a><strong>?</strong> – Combination immunotherapy with nivolumab and ipilimumab in locally advanced or metastatic UC remains investigational [<a href="#rid82">82,84-87</a>], and further studies with longer follow-up are needed.</p><p></p><p class="bulletIndent1">In an open-label phase II study (CheckMate 032), 274 patients with advanced or metastatic UC who progressed on previous platinum-based chemotherapy were randomly assigned to single-agent <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> 3 mg/kg until progression or to four cycles of either nivolumab 3 mg/kg plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> 1 mg/kg or nivolumab 1 mg/kg plus ipilimumab 3 mg/kg, followed in either case by nivolumab 3 mg/kg maintenance therapy [<a href="#rid82">82</a>].</p><p></p><p class="bulletIndent1">After a minimum follow-up of eight months, the combination of <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> 1 mg/kg plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> 3 mg/kg demonstrated a response rate of 38 percent (versus 26 percent with nivolumab alone and 27 percent with nivolumab 3 mg/kg plus ipilimumab 1 mg/kg). This combination group also demonstrated a nonsignificant trend towards improved PFS and OS (median PFS 4.9 months versus 2.8 and 2.6 months; median OS 15.3 months versus 9.9 and 7.4 months, respectively). Responses occurred in all treatment groups regardless of PD-L1 expression.</p><p></p><p class="bulletIndent1">Grade ≥3 treatment-related toxicities, as well as serious adverse events, occurred more frequently in the <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> combination arms. However, many of the treatment-related toxicities resolved with immune-modulating medications.</p><p></p><p><a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">Nivolumab</a> is approved by the US Food and Drug Administration (FDA) for patients with advanced or metastatic UC who progress during or after previous platinum-based chemotherapy either for metastatic disease or for progressive disease less than 12 months after adjuvant or neoadjuvant chemotherapy.</p><p class="headingAnchor" id="H2187478042"><span class="h3">Avelumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="112481" href="/d/drug information/112481.html" rel="external">Avelumab</a> is an option for patients with advanced or metastatic UC who progress on platinum-based chemotherapy.</p><p>In a combined analysis of two phase I expansion cohorts, 161 patients with advanced or metastatic UC who progressed on platinum-based therapy were treated with <a class="drug drug_general" data-topicid="112481" href="/d/drug information/112481.html" rel="external">avelumab</a> [<a href="#rid88">88</a>]. At median follow-up of at least six months:</p><p class="bulletIndent1"><span class="glyph">●</span>Objective response rate for the entire cohort was 17 percent, including a complete response rate of 6 percent. The objective response rate was higher for PD-L1 positive versus negative tumors (24 versus 14 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Common treatment-related adverse events were infusion-related reaction (29 percent; all grade 1 to 2) and fatigue (16 percent). The grade ≥3 toxicity rate was 8 percent; the most common was fatigue (2 percent). One treatment-related death occurred (pneumonitis).</p><p></p><p><a class="drug drug_general" data-topicid="112481" href="/d/drug information/112481.html" rel="external">Avelumab</a> is approved by the US FDA for the treatment of advanced UC that progressed during or after platinum-based chemotherapy.</p><p class="headingAnchor" id="H3706733998"><span class="h3">Other agents</span><span class="headingEndMark"> — </span>We do not offer <a class="drug drug_general" data-topicid="112994" href="/d/drug information/112994.html" rel="external">durvalumab</a> or <a class="drug drug_general" data-topicid="108314" href="/d/drug information/108314.html" rel="external">atezolizumab</a> to patients with advanced or metastatic UC that is refractory to platinum-based chemotherapy. In the United States, accelerated approval for these agents was voluntarily withdrawn for this indication when they both failed to confer an OS benefit over chemotherapy in separate randomized phase III trials (DANUBE for durvalumab [<a href="#rid89">89</a>] and IMvigor211 for atezolizumab [<a href="#rid90">90,91</a>]).</p><p class="headingAnchor" id="H1861151699"><span class="h2">Prior pembrolizumab plus enfortumab vedotin</span><span class="headingEndMark"> — </span>For patients who progress on <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> plus <a class="drug drug_general" data-topicid="126407" href="/d/drug information/126407.html" rel="external">enfortumab vedotin</a>, the optimal approach to second-line therapy is not established. Data for second-line therapy are limited for this population, and the approach to therapy is mainly based on clinical rationale. Patients should be encouraged to enroll in clinical trials, including those evaluating the use of other targeted agents as second-line therapy.</p><p>For patients who are not eligible for clinical trials, potential options for second-line therapy include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>For cisplatin-eligible patients  (<a class="graphic graphic_table graphicRef143615" href="/d/graphic/143615.html" rel="external">table 2</a>), we suggest cisplatin-based chemotherapy, with <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> as a reasonable alternative. Selection of therapy depends upon patient performance status, comorbidities, and toxicities related to prior therapy. For example, cisplatin-based therapy may be preferred for medically fit patients, whereas gemcitabine plus carboplatin may be preferred for less medically fit patients and/or those with cumulative peripheral neuropathy related to <a class="drug drug_general" data-topicid="126407" href="/d/drug information/126407.html" rel="external">enfortumab vedotin</a>. (See <a class="local">'Cisplatin-based chemotherapy'</a> above and <a class="local">'Gemcitabine plus carboplatin'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For cisplatin-ineligible patients, we offer second-line therapy with <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a>, although data are limited for this approach. (See <a class="local">'Gemcitabine plus carboplatin'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients whose tumors harbor a fibroblast growth factor receptor (<em>FGFR</em>) alteration may also be evaluated for <a class="drug drug_general" data-topicid="121054" href="/d/drug information/121054.html" rel="external">erdafitinib</a>, regardless of platinum-eligibility. UpToDate experts consider patients who have been treated with <a class="drug drug_general" data-topicid="126407" href="/d/drug information/126407.html" rel="external">enfortumab vedotin</a> (a targeted antibody conjugated to a microtubule inhibitor) as having received prior chemotherapy. (See <a class="local">'Erdafitinib'</a> below.)</p><p></p><p class="headingAnchor" id="H1740518999"><span class="h2">Prior nivolumab plus gemcitabine and cisplatin</span><span class="headingEndMark"> — </span>For patients who progress on <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> and <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, we offer second-line therapy using a similar approach to those who progress on both platinum-based chemotherapy and immunotherapy. (See <a class="local">'Prior platinum and immunotherapy'</a> below.)</p><p>Clinical trial enrollment is also encouraged, where available.</p><p class="headingAnchor" id="H3800710683"><span class="h1">LATER-LINE THERAPY</span><span class="headingEndMark"> — </span>Later-lines of therapy are based on multiple clinical factors including prior therapies received, specific tumor molecular alterations (ie, fibroblast growth factor receptor [<em>FGFR</em>] status), as well as patient comorbidities, preferences, and treatment goals.</p><p class="headingAnchor" id="H948820926"><span class="h2">Prior platinum and immunotherapy</span><span class="headingEndMark"> — </span>For patients with advanced or metastatic urothelial carcinoma (UC) who relapse following treatment with a platinum-based regimen and immunotherapy, our approach is as follows:</p><p class="headingAnchor" id="H21"><span class="h3">FGFR mutation negative</span><span class="headingEndMark"> — </span>For patients with disease lacking an <em>FGFR2</em> or<em> FGFR3</em> alteration who were previously treated with both platinum-based chemotherapy and immunotherapy with a programmed cell death 1 protein (PD-1) or PD-1 ligand (PD-L1) inhibitor, we suggest the antibody-drug conjugate <a class="drug drug_general" data-topicid="126407" href="/d/drug information/126407.html" rel="external">enfortumab vedotin</a> (if not previously received), as this agent improved overall survival (OS) in a randomized phase III trial. (See <a class="local">'Enfortumab vedotin'</a> below.)</p><p><a class="drug drug_general" data-topicid="127999" href="/d/drug information/127999.html" rel="external">Sacituzumab govitecan</a>, another antibody-drug conjugate, is also a reasonable alternative in this setting, with a different toxicity profile from other targeted agents. Further data are also needed to determine a survival benefit for this agent. (See <a class="local">'Sacituzumab govitecan'</a> below.)</p><p class="headingAnchor" id="H3753527401"><span class="h4">Enfortumab vedotin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="126407" href="/d/drug information/126407.html" rel="external">Enfortumab vedotin</a> improved both OS and progression-free survival (PFS) over chemotherapy in a randomized phase III trial [<a href="#rid92">92,93</a>].</p><p>Based on data from phase I and II trials [<a href="#rid94">94,95</a>], <a class="drug drug_general" data-topicid="126407" href="/d/drug information/126407.html" rel="external">enfortumab vedotin</a> was evaluated in a phase III clinical trial (EV-301) of 608 patients with locally advanced unresectable or metastatic UC (including those with squamous differentiation or mixed cell types) previously treated with platinum-based chemotherapy and PD-1/PD-L1 inhibitor [<a href="#rid92">92,93</a>]; however, those who progressed on maintenance <a class="drug drug_general" data-topicid="112481" href="/d/drug information/112481.html" rel="external">avelumab</a> were not included in this trial. Patients were randomly assigned to either enfortumab vedotin or investigator's choice of chemotherapy (<a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a>, <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a>, or vinflunine). At median follow-up of approximately 24 months, compared with chemotherapy, enfortumab vedotin improved OS (median 13 versus 9 months, hazard ratio [HR] 0.70, 95% CI 0.58-0.85), PFS (median 6 versus 4 months, HR 0.63, 95% CI 0.53-0.76), and overall response rates (41 versus 19 percent) [<a href="#rid93">93</a>].</p><p>Grade ≥3 toxicity rates for any adverse event were similar between the two treatment arms (52 versus 51 percent). Grade ≥3 toxicities specifically associated with <a class="drug drug_general" data-topicid="126407" href="/d/drug information/126407.html" rel="external">enfortumab vedotin</a> included rash (15 percent), peripheral neuropathy (5 percent), and hyperglycemia (4 percent). Ocular toxicities, pneumonitis (eg, interstitial lung disease) [<a href="#rid96">96,97</a>], and severe cutaneous adverse reactions, including cases of Steven-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have also been reported with this agent. (See <a class="local">'Toxicity'</a> above.)</p><p><a class="drug drug_general" data-topicid="126407" href="/d/drug information/126407.html" rel="external">Enfortumab vedotin</a> is approved by the US Food and Drug Administration (FDA) for patients with locally advanced or metastatic UC who have progressed on both platinum-based chemotherapy and immunotherapy [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H346685631"><span class="h4">Sacituzumab govitecan</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="127999" href="/d/drug information/127999.html" rel="external">Sacituzumab govitecan</a> is an antibody-drug conjugate that targets Trop-2, a transmembrane glycoprotein highly expressed in most UC, and is coupled with SN-38, an active metabolite of <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a>. Sacituzumab govitecan dose is administered with a dose of 10 mg/kg once weekly on days 1 and 8 every 21 days until disease progression or unacceptable toxicity. Patients should be premedicated to prevent infusion reactions and treatment-induced nausea and vomiting, which is discussed separately. (See  <a class="medical medical_review" href="/d/html/2811.html" rel="external">"Infusion-related reactions to therapeutic monoclonal antibodies used for cancer therapy", section on 'Use of premedication to prevent infusion reactions'</a>.)</p><p>In an open-label phase II trial (TROPHY-U-01), 113 patients with advanced UC previously treated with platinum-based chemotherapy or immunotherapy (either with a PD-1 or PD-L1 inhibitor) received <a class="drug drug_general" data-topicid="127999" href="/d/drug information/127999.html" rel="external">sacituzumab govitecan</a> [<a href="#rid98">98</a>]. In this study, objective and complete response rates were 27 and 5 percent, respectively. Median OS and PFS were 5 and 11 months, respectively [<a href="#rid98">98</a>].</p><p>Grade ≥3 toxicities included neutropenia (35 percent), leukopenia (18 percent), anemia (14 percent), diarrhea and febrile neutropenia (10 percent each), lymphopenia (7 percent), urinary tract infection (6 percent), and fatigue and nausea (4 percent each). Neutropenia was among the most common adverse reactions leading to dose interruption, and approximately one-third (30 percent) of patients used growth factor support, such as granulocyte-colony stimulating factor (G-CSF). There was one treatment-related death due to sepsis from febrile neutropenia.</p><p><a class="drug drug_general" data-topicid="127999" href="/d/drug information/127999.html" rel="external">Sacituzumab govitecan</a> has accelerated approval from the US FDA for patients with locally advanced or metastatic UC who have previously received a platinum-containing chemotherapy and either a PD-1 or PD-L1 inhibitor [<a href="#rid99">99</a>]. However, this approval remains contingent on further randomized data confirming survival benefit and acceptable toxicity for this agent.</p><p class="headingAnchor" id="H2013250689"><span class="h3">FGFR mutation positive</span></p><p class="headingAnchor" id="H1808198910"><span class="h4">Erdafitinib</span><span class="headingEndMark"> — </span>For patients with advanced or metastatic UC and an <em>FGFR</em> 3 or 2 genetic alteration, we suggest <a class="drug drug_general" data-topicid="121054" href="/d/drug information/121054.html" rel="external">erdafitinib</a>, an <em>FGFR</em> inhibitor, as this approach improved OS in a phase III trial. Although erdafitinib is approved after platinum-based chemotherapy in this population, we use it after disease progression on both platinum-containing chemotherapy (or an antibody-drug conjugate) and immunotherapy.</p><p><a class="drug drug_general" data-topicid="126407" href="/d/drug information/126407.html" rel="external">Enfortumab vedotin</a>, if not previously received, and <a class="drug drug_general" data-topicid="127999" href="/d/drug information/127999.html" rel="external">sacituzumab govitecan</a> are also alternative options in this patient population. These agents have not been specifically tested in patients with <em>FGFR</em> alterations, and further data are necessary to confirm an OS benefit. Randomized trials are also needed to direct the appropriate sequencing of these agents relative to <a class="drug drug_general" data-topicid="121054" href="/d/drug information/121054.html" rel="external">erdafitinib</a>. (See <a class="local">'Enfortumab vedotin'</a> above and <a class="local">'Sacituzumab govitecan'</a> above.)</p><p>Patients should be selected for therapy with <a class="drug drug_general" data-topicid="121054" href="/d/drug information/121054.html" rel="external">erdafitinib</a> based on the US FDA-approved companion diagnostic test for <em>FGFR2/3</em> somatic mutations or translocations using reverse transcription polymerase chain reaction (RT-PCR) [<a href="#rid100">100,101</a>]. Tumors may be assessed either at the initial onset of metastatic disease or upon progression after initial lines of systemic therapy. Other genomic platforms may also be used [<a href="#rid101">101</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>The efficacy of <a class="drug drug_general" data-topicid="121054" href="/d/drug information/121054.html" rel="external">erdafitinib</a> was initially demonstrated in early phase clinical trials [<a href="#rid102">102-106</a>]. This included an open-label phase II trial (BLC2001), which demonstrated an objective response rate of 40 percent and median OS of 11 months [<a href="#rid102">102,104</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Based on these data, <a class="drug drug_general" data-topicid="121054" href="/d/drug information/121054.html" rel="external">erdafitinib</a> was evaluated in an open-label phase III trial (THOR, cohort 1) of 266 patients with advanced unresectable or metastatic UC with an <em>FGFR2</em> or <em>FGFR3</em> mutation who progressed on one or two prior lines of therapy, including a PD-(L)1 inhibitor [<a href="#rid107">107</a>]. Patients were randomly assigned to either erdafitinib or investigator's choice of chemotherapy (<a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> or vinflunine).</p><p></p><p class="bulletIndent1">At median follow-up of 16 months, <a class="drug drug_general" data-topicid="121054" href="/d/drug information/121054.html" rel="external">erdafitinib</a> improved OS and PFS relative to chemotherapy (median OS 12 versus 8 months, HR 0.64, 95% CI 0.47-0.88; median PFS 6 versus 3 months, HR 0.58, 95% CI 0.44-0.78) [<a href="#rid107">107</a>]. An OS benefit was seen across all clinically relevant subgroups, including those with <em>FGFR</em> mutations or translocations. Erdafitinib also improved objective response rates (46 versus 12 percent) and complete response rates (7 versus 1 percent) compared with chemotherapy.</p><p></p><p class="bulletIndent1">Grade ≥3 toxicity rates were similar between the two treatment arms (46 percent each). For <a class="drug drug_general" data-topicid="121054" href="/d/drug information/121054.html" rel="external">erdafitinib</a>, grade ≥3 toxicities included palmar-plantar erythrodysesthesia (10 percent), stomatitis (8 percent), onycholysis (6 percent), hyperphosphatemia (5 percent), and diarrhea (3 percent), central serous retinopathy (CSR), and eye disorders other than CSR (2 percent each). (See  <a class="medical medical_review" href="/d/html/114914.html" rel="external">"Nephrotoxicity of molecularly targeted agents and immunotherapy", section on 'FGFR inhibitors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="121054" href="/d/drug information/121054.html" rel="external">Erdafitinib</a> was also compared to <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> in an open-label phase III trial (THOR, cohort 2) of 351 patients with advanced unresectable or metastatic UC with an <em>FGFR2</em> or <em>FGFR3</em> mutation who progressed on one prior therapy and were naïve to a PD-L1 inhibitor [<a href="#rid108">108</a>]. At median follow-up of 33 months, erdafitinib demonstrated similar OS (median 11 months each, HR 1.18, 95% CI 0.92-1.51) relative to pembrolizumab.</p><p></p><p>Based on the phase II BLC2001 trial, the US FDA granted accelerated approval for <a class="drug drug_general" data-topicid="121054" href="/d/drug information/121054.html" rel="external">erdafitinib</a> for patients with locally advanced or metastatic UC with a susceptible <em>FGFR3</em> or <em>FGFR2</em> genetic alteration that has progressed during or following platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant chemotherapy [<a href="#rid100">100</a>].</p><p class="headingAnchor" id="H2572763558"><span class="h2">Cisplatin-ineligible, no prior platinum, prior immunotherapy</span><span class="headingEndMark"> — </span>For patients who are ineligible for cisplatin-based chemotherapy, have not received prior platinum-based chemotherapy, and progress on immunotherapy, options include <a class="drug drug_general" data-topicid="126407" href="/d/drug information/126407.html" rel="external">enfortumab vedotin</a>, if not previously received, or chemotherapy not previously received.</p><p class="headingAnchor" id="H2838411997"><span class="h3">Enfortumab vedotin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="126407" href="/d/drug information/126407.html" rel="external">Enfortumab vedotin</a> is active in patients with metastatic UC who are ineligible for cisplatin-based chemotherapy and have progressed on prior immunotherapy. This agent was evaluated in an open-label phase II trial (EV-201) of 91 patients with locally advanced or metastatic disease who were ineligible for <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, had not received prior platinum-based chemotherapy in the locally advanced or metastatic setting, and were previously treated with either a PD-1 or PD-L1 inhibitor [<a href="#rid97">97</a>]. In this study, enfortumab vedotin had an objective response rate of 52 percent, including complete and partial response rates of 20 and 31 percent, respectively. Grade ≥3 toxicities included neutropenia (9 percent), maculopapular rash (8 percent), and fatigue (7 percent). Four patients died of treatment-related toxicities including acute kidney injury, metabolic acidosis, multiple organ dysfunction syndrome, and pneumonitis.</p><p>Based on these data, <a class="drug drug_general" data-topicid="126407" href="/d/drug information/126407.html" rel="external">enfortumab vedotin</a> received regulatory approval from the US FDA in patients with locally advanced or metastatic UC who are ineligible for cisplatin-based chemotherapy and have previously received one or more prior lines of therapy [<a href="#rid16">16</a>]. Further randomized trials directly comparing enfortumab vedotin with other agents in this specific patient population are necessary.</p><p>The efficacy of <a class="drug drug_general" data-topicid="126407" href="/d/drug information/126407.html" rel="external">enfortumab vedotin</a> in patients who have relapsed after both platinum-based chemotherapy and immunotherapy is discussed above. (See <a class="local">'Enfortumab vedotin'</a> above.)</p><p class="headingAnchor" id="H2633828636"><span class="h3">Chemotherapy</span><span class="headingEndMark"> — </span>In patients with treatment-refractory disease who are ineligible for cisplatin-based chemotherapy, single-agent chemotherapy is a reasonable alternative to <a class="drug drug_general" data-topicid="126407" href="/d/drug information/126407.html" rel="external">enfortumab vedotin</a>. Single-agent chemotherapy may also be used for cisplatin-ineligible patients without access to enfortumab vedotin. Patients may be offered alternative chemotherapy not previously received. (See <a class="local">'Single-agent chemotherapy'</a> above.)</p><p class="headingAnchor" id="H1685708394"><span class="h2">Ineligible for targeted therapy</span><span class="headingEndMark"> — </span>Patients who are ineligible for or decline targeted therapy may be offered single-agent chemotherapy as an alternative. Patients should be encouraged to enroll in clinical trials, where available.</p><p class="headingAnchor" id="H1574391740"><span class="h3">Single-agent chemotherapy</span><span class="headingEndMark"> — </span>Some chemotherapy agents have clinical activity in treatment-refractory advanced or metastatic UC, with objective response rates ranging between 10 and 28 percent. Selection of therapy is based on patient and provider preference and prior chemotherapy received.</p><p class="headingAnchor" id="H3008312923"><span class="h4">Vinflunine</span><span class="headingEndMark"> — </span>Vinflunine is active in treatment-refractory disease [<a href="#rid109">109,110</a>]. In the phase III trial of 370 patients with treatment-refractory advanced or metastatic UC, vinflunine improved survival relative to best supportive care (6.9 versus 4.6 months, hazard ratio [HR] 0.88, 95% CI 0.69-1.12) and an objective response rate of 9 percent.</p><p>Vinflunine is approved in Europe for second-line treatment of UC.</p><p class="headingAnchor" id="H3511628273"><span class="h4">Pemetrexed</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10098" href="/d/drug information/10098.html" rel="external">Pemetrexed</a> is active in treatment-refractory advanced or metastatic UC. In a phase II study of 47 previously treated patients, the objective response rate for 28 percent, including three complete responses (6 percent) [<a href="#rid111">111</a>]; median OS was 10 months. By contrast, pemetrexed had minimal efficacy in a separate phase II study [<a href="#rid112">112</a>].</p><p class="headingAnchor" id="H4015404572"><span class="h4">Taxanes</span><span class="headingEndMark"> — </span>Taxanes that have clinical activity in treatment-refractory disease include <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> [<a href="#rid51">51,58,113</a>], nanoparticle albumin-bound paclitaxel (<a class="drug drug_general" data-topicid="10159" href="/d/drug information/10159.html" rel="external">nabpaclitaxel</a>) [<a href="#rid58">58,114</a>], and <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> [<a href="#rid54">54</a>].</p><p>In a randomized phase II trial of 199 patients with platinum-refractory metastatic UC, <a class="drug drug_general" data-topicid="10159" href="/d/drug information/10159.html" rel="external">nabpaclitaxel</a> and <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> demonstrated similar OS (7.5 versus 8.8 months, HR 0.95, 90% CI 0.70-1.30), PFS (3.4 versus 3.0 months, HR 0.92, 90% CI 0.68-1.23), and objective response rate (22 versus 25 percent) [<a href="#rid58">58</a>].</p><p class="headingAnchor" id="H3280749044"><span class="h4">Other agents</span><span class="headingEndMark"> — </span>Other options include <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> [<a href="#rid55">55</a>], <a class="drug drug_general" data-topicid="8552" href="/d/drug information/8552.html" rel="external">ifosfamide</a> [<a href="#rid50">50,115</a>], and <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> [<a href="#rid40">40</a>].</p><p class="headingAnchor" id="H454302187"><span class="h1">INVESTIGATIONAL AGENTS</span><span class="headingEndMark"> — </span>Various agents remain under investigation in the treatment of patients with treatment-refractory metastatic UC. These include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Soluble EphB4-human serum albumin (sEphB4-HSA)</strong> – This agent was evaluated in combination with <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> in a phase II trial of 70 patients with locally advanced or metastatic UC that recurred or progressed on platinum-based chemotherapy [<a href="#rid116">116</a>]. At median follow-up of 23 months, in the entire study population the objective response rate was 37 percent, and median overall survival (OS) was 15 months. Among patients whose tumors expressed EphrinB2, the target of sEphB4-HSA, the objective response rate and complete response rate were 52 and 24 percent respectively, and median OS was 22 months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rogaratinib</strong> – Rogaratinib, an oral pan-fibroblast growth factor receptor (FGFR1-4) inhibitor, was investigated in a randomized phase II/III trial (FORT-1) of 175 patients with advanced or metastatic fibroblast growth factor receptor 1 (<em>FGFR1</em>)- or <em>FGFR3</em>-positive (based on RNA overexpression) UC previously treated with platinum-based chemotherapy [<a href="#rid117">117</a>]. At median follow-up of 11 months, in the entire study population, rogaratinib did not improve objective response rate or OS compared with investigator's choice of chemotherapy (<a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a>, <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a>, or vinflunine). In a retrospective exploratory analysis, the objective response rate was higher for rogaratinib for the subset of patients with tumors positive for <em>FGFR3</em> mRNA and with <em>FGFR3</em> DNA alterations versus the entire study population (52.4 versus 20.7 percent).</p><p></p><p class="headingAnchor" id="H2642063347"><span class="h1">SPECIAL CONSIDERATIONS</span></p><p class="headingAnchor" id="H2809276636"><span class="h2">Oligometastatic disease</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Based on an expert opinion paper, the definition of oligometastatic disease for urothelial bladder cancer is a maximum of three metastatic sites (other than the pelvic lymph nodes) that are all resectable or amenable to stereotactic body radiotherapy (SBRT) [<a href="#rid118">118</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – There are limited data for the optimal treatment approach. For patients with oligometastatic UC and no disease progression on initial systemic platinum-based chemotherapy, maintenance therapy with <a class="drug drug_general" data-topicid="112481" href="/d/drug information/112481.html" rel="external">avelumab</a> is one appropriate management strategy that confers an overall survival advantage. (See <a class="local">'Maintenance therapy'</a> above.)</p><p></p><p class="bulletIndent1">Alternatively, select patients with oligometastatic disease, good performance status, and minimal comorbidities who have a good partial response to initial systemic therapy may be candidates for local therapy (surgical metastasectomy or SBRT) to the remaining sites of disease [<a href="#rid118">118-120</a>]. However, this strategy has not been evaluated in high-quality randomized clinical trials. Multidisciplinary input is necessary for patients being evaluated for this approach. Patient selection may also be influenced by age and anticipated life expectancy. Restaging imaging studies to confirm oligometastatic disease must be obtained after the completion of systemic therapy and prior to evaluating for local therapy. Patients who are disease-free after local therapy to oligometastatic disease also require close surveillance for disease recurrence.</p><p></p><p class="headingAnchor" id="H23"><span class="h2">Non-urothelial bladder cancer</span><span class="headingEndMark"> — </span>Urothelial carcinomas constitute most bladder cancers in the United States, while squamous cell carcinomas and adenocarcinomas comprise a small fraction of bladder cancers. The management of non-urothelial bladder cancer, including chemotherapy for the treatment of advanced disease, is discussed separately. (See  <a class="medical medical_review" href="/d/html/2964.html" rel="external">"Non-urothelial bladder cancer"</a>.)</p><p class="headingAnchor" id="H4073989692"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/15351.html" rel="external">"Patient education: Bladder cancer (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/873.html" rel="external">"Patient education: Bladder cancer diagnosis and staging (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/870.html" rel="external">"Patient education: Bladder cancer treatment; muscle invasive cancer (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/867.html" rel="external">"Patient education: Bladder cancer treatment; non-muscle invasive (superficial) cancer (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H2712525765"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/122007.html" rel="external">"Society guideline links: Bladder cancer"</a>.)</p><p class="headingAnchor" id="H24"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles</strong> – The approach to systemic therapy for locally advanced unresectable or metastatic urothelial carcinoma (UC) of the bladder and urinary tract is evolving. Systemic treatment options include antibody-drug conjugates, chemotherapy, immune checkpoint inhibitors, and targeted therapies, as single agents or in combination. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1">The goals of therapy include controlling tumor burden, treating cancer-related symptoms, and improving overall survival. Although treatment intent for most patients with bladder cancer is palliative, some patients may have a chance at curative intent therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial therapy </strong>– For patients with advanced unresectable or metastatic UC, we recommend initial therapy with <a class="drug drug_general" data-topicid="126407" href="/d/drug information/126407.html" rel="external">enfortumab vedotin</a> plus <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> rather than platinum-based chemotherapy  (<a class="graphic graphic_algorithm graphicRef111737" href="/d/graphic/111737.html" rel="external">algorithm 1</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Enfortumab vedotin plus pembrolizumab'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>However, some patients may decline, lack access to, or be poor candidates for <a class="drug drug_general" data-topicid="126407" href="/d/drug information/126407.html" rel="external">enfortumab vedotin</a> plus <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>, including those with poorly controlled neuropathy or autoimmune disease. In such cases, appropriate alternatives include <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> and <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, <strong>or</strong> cisplatin-based chemotherapy followed by maintenance immunotherapy for patients without disease progression. The optimal sequencing of chemotherapy and immunotherapy for initial therapy (concurrent versus sequential) is not established. (See <a class="local">'Nivolumab plus gemcitabine plus cisplatin'</a> above and <a class="local">'Cisplatin-based chemotherapy'</a> above.)</p><p></p><p class="bulletIndent2">Options for cisplatin-based chemotherapy include: </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">Methotrexate</a>, <a class="drug drug_general" data-topicid="10044" href="/d/drug information/10044.html" rel="external">vinblastine</a>, <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, and <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> (MVAC)  (<a class="graphic graphic_table graphicRef64950" href="/d/graphic/64950.html" rel="external">table 5</a>)</p><p class="bulletIndent3"><span class="glyph">-</span>Dose-dense MVAC  (<a class="graphic graphic_table graphicRef111814" href="/d/graphic/111814.html" rel="external">table 6</a>)</p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">Gemcitabine</a> plus <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> (GC)  (<a class="graphic graphic_table graphicRef53016" href="/d/graphic/53016.html" rel="external">table 7</a>)</p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">Paclitaxel</a>, <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a>, and <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> (PGC)  (<a class="graphic graphic_table graphicRef140871" href="/d/graphic/140871.html" rel="external">table 8</a>). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Other alternatives to <a class="drug drug_general" data-topicid="126407" href="/d/drug information/126407.html" rel="external">enfortumab vedotin</a> plus <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> include <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> or single-agent pembrolizumab  (<a class="graphic graphic_table graphicRef127101" href="/d/graphic/127101.html" rel="external">table 9</a>) (See <a class="local">'Gemcitabine plus carboplatin'</a> above and <a class="local">'Pembrolizumab'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subsequent-line therapy</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who progress on <a class="drug drug_general" data-topicid="126407" href="/d/drug information/126407.html" rel="external">enfortumab vedotin</a> plus <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>, we suggest cisplatin-based chemotherapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>), with <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> plus <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> as a reasonable alternative. For patients whose tumors harbor a fibroblast growth factor receptor (<em>FGFR</em>) alteration, <a class="drug drug_general" data-topicid="121054" href="/d/drug information/121054.html" rel="external">erdafitinib</a> is also a reasonable alternative. (See <a class="local">'Prior pembrolizumab plus enfortumab vedotin'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with advanced or metastatic UC who progress on both platinum-based chemotherapy and immunotherapy, or for those who are ineligible for these options, our approach is as follows (see <a class="local">'Prior platinum and immunotherapy'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong><em>FGFR </em></strong><strong>mutation positive</strong> – For patients with metastatic UC and an <em>FGFR</em> 3 or 2 genetic alteration, we suggest <a class="drug drug_general" data-topicid="121054" href="/d/drug information/121054.html" rel="external">erdafitinib</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). <a class="drug drug_general" data-topicid="126407" href="/d/drug information/126407.html" rel="external">Enfortumab vedotin</a> (if not already administered) and <a class="drug drug_general" data-topicid="127999" href="/d/drug information/127999.html" rel="external">sacituzumab govitecan</a> are acceptable alternatives. (See <a class="local">'FGFR mutation positive'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong><em>FGFR</em></strong><strong> mutation negative</strong> – For patients with metastatic UC lacking an <em>FGFR</em> 3 or 2 genetic alteration, options include <a class="drug drug_general" data-topicid="126407" href="/d/drug information/126407.html" rel="external">enfortumab vedotin</a> (if not already administered), <a class="drug drug_general" data-topicid="127999" href="/d/drug information/127999.html" rel="external">sacituzumab govitecan</a>, or single-agent chemotherapy. (See <a class="local">'FGFR mutation negative'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Later-line therapy includes single-agent chemotherapy agents, eg, vinflunine (where available), <a class="drug drug_general" data-topicid="10098" href="/d/drug information/10098.html" rel="external">pemetrexed</a>, taxanes, <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a>, <a class="drug drug_general" data-topicid="8552" href="/d/drug information/8552.html" rel="external">ifosfamide</a>, and <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a>. (See <a class="local">'Ineligible for targeted therapy'</a> above.)</p><p></p><p class="headingAnchor" id="H96595234"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Gary R MacVicar, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005; 23:4602.</a></li><li><a class="nounderline abstract_t">Bajorin DF, Dodd PM, Mazumdar M, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999; 17:3173.</a></li><li><a class="nounderline abstract_t">Bellmunt J, Albanell J, Paz-Ares L, et al. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine. Cancer 2002; 95:751.</a></li><li><a class="nounderline abstract_t">Lin CC, Hsu CH, Huang CY, et al. Prognostic factors for metastatic urothelial carcinoma treated with cisplatin and 5-fluorouracil-based regimens. Urology 2007; 69:479.</a></li><li><a class="nounderline abstract_t">Loehrer PJ Sr, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1992; 10:1066.</a></li><li><a class="nounderline abstract_t">Saxman SB, Propert KJ, Einhorn LH, et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1997; 15:2564.</a></li><li><a class="nounderline abstract_t">Stadler WM, Hayden A, von der Maase H, et al. Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer. Urol Oncol 2002; 7:153.</a></li><li><a class="nounderline abstract_t">Adibi M, McCormick B, Economides MP, et al. Five and Ten-Year Outcomes of Neoadjuvant Chemotherapy and Surgery for High-Risk Upper Tract Urothelial Carcinoma. Clin Genitourin Cancer 2022; 20:176.</a></li><li><a class="nounderline abstract_t">Bellmunt J, Choueiri TK, Fougeray R, et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 2010; 28:1850.</a></li><li><a class="nounderline abstract_t">Sonpavde G, Pond GR, Fougeray R, et al. Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. Eur Urol 2013; 63:717.</a></li><li><a class="nounderline abstract_t">Sarfaty M, Golkaram M, Funt SA, et al. Novel Genetic Subtypes of Urothelial Carcinoma With Differential Outcomes on Immune Checkpoint Blockade. J Clin Oncol 2023; 41:3225.</a></li><li><a class="nounderline abstract_t">Kardoust Parizi M, Margulis V, Compe Rat E, Shariat SF. The value and limitations of urothelial bladder carcinoma molecular classifications to predict oncological outcomes and cancer treatment response: A systematic review and meta-analysis. Urol Oncol 2021; 39:15.</a></li><li><a class="nounderline abstract_t">Wang S, Yuan X, Shen Z, et al. Therapeutic responses to chemotherapy or immunotherapy by molecular subtype in bladder cancer patients: A meta-analysis and systematic review. Investig Clin Urol 2023; 64:229.</a></li><li><a class="nounderline abstract_t">Galsky MD, Hahn NM, Rosenberg J, et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol 2011; 12:211.</a></li><li class="breakAll">Pembrolizumab: United States Food and Drug Administration Prescribing Label https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s136lbl.pdf (Accessed on April 12, 2023).</li><li class="breakAll">Enfortumab vedotin-ejfv for injection. United States Prescribing Information. US National Library of Medicine. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761137s020lbl.pdf (Accessed on April 12, 2023).</li><li><a class="nounderline abstract_t">Powles TB, Valderrrama BP, Gupta S, et al. LBA6 EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC). Ann Oncol 2023; 34; S2.</a></li><li><a class="nounderline abstract_t">van der Heijden MS, Sonpavde G, Powles T, et al. Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma. N Engl J Med 2023; 389:1778.</a></li><li><a class="nounderline abstract_t">Logothetis CJ, Dexeus FH, Finn L, et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 1990; 8:1050.</a></li><li><a class="nounderline abstract_t">Tannock I, Gospodarowicz M, Connolly J, Jewett M. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience. J Urol 1989; 142:289.</a></li><li><a class="nounderline abstract_t">Siefker-Radtke AO, Millikan RE, Tu SM, et al. Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer. J Clin Oncol 2002; 20:1361.</a></li><li><a class="nounderline abstract_t">Gabrilove JL, Jakubowski A, Scher H, et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 1988; 318:1414.</a></li><li><a class="nounderline abstract_t">Moore MJ, Iscoe N, Tannock IF. A phase II study of methotrexate, vinblastine, doxorubicin and cisplatin plus recombinant human granulocyte-macrophage colony stimulating factors in patients with advanced transitional cell carcinoma. J Urol 1993; 150:1131.</a></li><li><a class="nounderline abstract_t">Sternberg CN, de Mulder PH, Schornagel JH, et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 2001; 19:2638.</a></li><li><a class="nounderline abstract_t">Sternberg CN, de Mulder P, Schornagel JH, et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 2006; 42:50.</a></li><li><a class="nounderline abstract_t">von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18:3068.</a></li><li><a class="nounderline abstract_t">von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study. J Clin Oncol 2023; 41:3881.</a></li><li><a class="nounderline abstract_t">Adamo V, Magno C, Spitaleri G, et al. Phase II study of gemcitabine and cisplatin in patients with advanced or metastatic bladder cancer: long-term follow-up of a 3-week regimen. Oncology 2005; 69:391.</a></li><li><a class="nounderline abstract_t">Soto Parra H, Cavina R, Latteri F, et al. Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study. Ann Oncol 2002; 13:1080.</a></li><li><a class="nounderline abstract_t">Als AB, Sengelov L, Von Der Maase H. Gemcitabine and cisplatin in locally advanced and metastatic bladder cancer; 3- or 4-week schedule? Acta Oncol 2008; 47:110.</a></li><li><a class="nounderline abstract_t">Bamias A, Dafni U, Karadimou A, et al. Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03). Ann Oncol 2013; 24:1011.</a></li><li><a class="nounderline abstract_t">Bellmunt J, von der Maase H, Mead GM, et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol 2012; 30:1107.</a></li><li><a class="nounderline abstract_t">Hoimes CJ, Flaig TW, Milowsky MI, et al. Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer. J Clin Oncol 2023; 41:22.</a></li><li><a class="nounderline abstract_t">O'Donnell PH, Milowsky MI, Petrylak DP, et al. Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer. J Clin Oncol 2023; 41:4107.</a></li><li><a class="nounderline abstract_t">De Santis M, Bellmunt J, Mead G, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol 2012; 30:191.</a></li><li><a class="nounderline abstract_t">Dogliotti L, Cartenì G, Siena S, et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol 2007; 52:134.</a></li><li><a class="nounderline abstract_t">Dreicer R, Manola J, Roth BJ, et al. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Cancer 2004; 100:1639.</a></li><li><a class="nounderline abstract_t">Petrioli R, Frediani B, Manganelli A, et al. Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study. Cancer 1996; 77:344.</a></li><li><a class="nounderline abstract_t">Sternberg CN, Calabrò F, Pizzocaro G, et al. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer 2001; 92:2993.</a></li><li><a class="nounderline abstract_t">Meluch AA, Greco FA, Burris HA 3rd, et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. J Clin Oncol 2001; 19:3018.</a></li><li><a class="nounderline abstract_t">Li J, Juliar B, Yiannoutsos C, et al. Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study. J Clin Oncol 2005; 23:1185.</a></li><li><a class="nounderline abstract_t">Calabrò F, Lorusso V, Rosati G, et al. Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma. Cancer 2009; 115:2652.</a></li><li><a class="nounderline abstract_t">Gitlitz BJ, Baker C, Chapman Y, et al. A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma. Cancer 2003; 98:1863.</a></li><li><a class="nounderline abstract_t">Ardavanis A, Tryfonopoulos D, Alexopoulos A, et al. Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study. Br J Cancer 2005; 92:645.</a></li><li><a class="nounderline abstract_t">Sadeghi S, Groshen SG, Tsao-Wei DD, et al. Phase II California Cancer Consortium Trial of Gemcitabine-Eribulin Combination in Cisplatin-Ineligible Patients With Metastatic Urothelial Carcinoma: Final Report (NCI-9653). J Clin Oncol 2019; 37:2682.</a></li><li><a class="nounderline abstract_t">Balar AV, Castellano D, O'Donnell PH, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol 2017; 18:1483.</a></li><li><a class="nounderline abstract_t">Vuky J, Balar AV, Castellano D, et al. Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer. J Clin Oncol 2020; 38:2658.</a></li><li><a class="nounderline abstract_t">Balar AV, Castellano DE, Grivas P, et al. Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up. Ann Oncol 2023; 34:289.</a></li><li><a class="nounderline abstract_t">Raghavan D, Shipley WU, Garnick MB, et al. Biology and management of bladder cancer. N Engl J Med 1990; 322:1129.</a></li><li><a class="nounderline abstract_t">Witte RS, Elson P, Bono B, et al. Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J Clin Oncol 1997; 15:589.</a></li><li><a class="nounderline abstract_t">Dreicer R, Gustin DM, See WA, Williams RD. Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy. J Urol 1996; 156:1606.</a></li><li><a class="nounderline abstract_t">Roth BJ, Dreicer R, Einhorn LH, et al. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 1994; 12:2264.</a></li><li><a class="nounderline abstract_t">de Wit R, Kruit WH, Stoter G, et al. Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients. Br J Cancer 1998; 78:1342.</a></li><li><a class="nounderline abstract_t">McCaffrey JA, Hilton S, Mazumdar M, et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 1997; 15:1853.</a></li><li><a class="nounderline abstract_t">Lorusso V, Pollera CF, Antimi M, et al. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur J Cancer 1998; 34:1208.</a></li><li><a class="nounderline abstract_t">Moore MJ, Tannock IF, Ernst DS, et al. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 1997; 15:3441.</a></li><li><a class="nounderline abstract_t">García-Donas J, Font A, Pérez-Valderrama B, et al. Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial. Lancet Oncol 2017; 18:672.</a></li><li><a class="nounderline abstract_t">Sridhar SS, Blais N, Tran B, et al. Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients With Platinum-Refractory Metastatic Urothelial Cancer: The Canadian Cancer Trials Group BL.12 Randomized Clinical Trial. JAMA Oncol 2020; 6:1751.</a></li><li class="breakAll">First-Line Nivolumab/Ipilimumab Fails to Improve OS Vs Chemotherapy in PD-L1–Low Unresectable or Metastatic Urothelial Carcinoma https://www.cancernetwork.com/view/first-line-nivolumab-ipilimumab-fails-to-improve-os-in-vs-chemotherapy-in-pd-l1-low-unresectable-or-metastatic-urothelial-carcinoma (Accessed on November 02, 2023).</li><li><a class="nounderline abstract_t">Powles T, Csőszi T, Özgüroğlu M, et al. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol 2021; 22:931.</a></li><li><a class="nounderline abstract_t">Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 2017; 389:67.</a></li><li><a class="nounderline abstract_t">Galsky MD, Arija JÁA, Bamias A, et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2020; 395:1547.</a></li><li><a class="nounderline abstract_t">Grande E, Arranz JÁ, De Santis M, et al. Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study. Lancet Oncol 2024; 25:29.</a></li><li><a class="nounderline abstract_t">Bamias A, Davis ID, Galsky MD, et al. Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study. Lancet Oncol 2024; 25:46.</a></li><li class="breakAll">Atezolizumab: US Food and Drug Administration Prescribing Label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s050lbl.pdf (Accessed on December 08, 2022).</li><li><a class="nounderline abstract_t">Iacovelli R, Ciccarese C, Brunelli M, et al. First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin. Ann Oncol 2022; 33:1179.</a></li><li><a class="nounderline abstract_t">Powles T, Park SH, Voog E, et al. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. N Engl J Med 2020; 383:1218.</a></li><li><a class="nounderline abstract_t">Powles T, Park SH, Caserta C, et al. Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up. J Clin Oncol 2023; 41:3486.</a></li><li class="breakAll">VENTANA PD-L1 (SP263) Assay (United States Food and Drug Administration Information) https://www.accessdata.fda.gov/cdrh_docs/pdf16/p160046c.pdf (Accessed on June 10, 2020).</li><li><a class="nounderline abstract_t">Powles T, Sridhar SS, Loriot Y, et al. Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial. Nat Med 2021; 27:2200.</a></li><li><a class="nounderline abstract_t">Grivas P, Park SH, Voog E, et al. Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial. Eur Urol 2023; 84:95.</a></li><li><a class="nounderline abstract_t">Loriot Y, Powles T, Climent Duran MA, et al. Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 subgroup analysis based on duration and cycles of 1L chemotherapy. J Clin Oncol 2021; 6S;438.</a></li><li><a class="nounderline abstract_t">Grivas P, Kopyltsov E, Su PJ, et al. Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma. Eur Urol 2023; 83:320.</a></li><li class="breakAll">Avelumab injection. United States Prescribing Information. US National Library of Medicine. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761049s009lbl.pdf (Accessed on July 02, 2020).</li><li><a class="nounderline abstract_t">Galsky MD, Mortazavi A, Milowsky MI, et al. Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer. J Clin Oncol 2020; 38:1797.</a></li><li><a class="nounderline abstract_t">Bellmunt Molins J, García-Donas Jiménez J, Valderrama BP, et al. Final Overall Survival Analysis of the SOGUG Phase 2 MAJA Study: Maintenance Vinflunine Versus Best Supportive Care After First-Line Chemotherapy in Advanced Urothelial Carcinoma. Clin Genitourin Cancer 2020; 18:452.</a></li><li><a class="nounderline abstract_t">Crabb SJ, Hussain S, Soulis E, et al. A Randomized, Double-Blind, Biomarker-Selected, Phase II Clinical Trial of Maintenance Poly ADP-Ribose Polymerase Inhibition With Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma. J Clin Oncol 2023; 41:54.</a></li><li><a class="nounderline abstract_t">Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med 2017; 376:1015.</a></li><li><a class="nounderline abstract_t">Vaughn DJ, Bellmunt J, Fradet Y, et al. Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer. J Clin Oncol 2018; 36:1579.</a></li><li><a class="nounderline abstract_t">Fradet Y, Bellmunt J, Vaughn DJ, et al. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of &gt;2 years of follow-up. Ann Oncol 2019; 30:970.</a></li><li><a class="nounderline abstract_t">Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol 2017; 18:312.</a></li><li><a class="nounderline abstract_t">Sharma P, Siefker-Radtke A, de Braud F, et al. Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results. J Clin Oncol 2019; 37:1608.</a></li><li><a class="nounderline abstract_t">Sharma P, Callahan MK, Bono P, et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol 2016; 17:1590.</a></li><li><a class="nounderline abstract_t">McGregor BA, Campbell MT, Xie W, et al. Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies. Cancer 2021; 127:840.</a></li><li><a class="nounderline abstract_t">Grimm MO, Schmitz-Dräger BJ, Zimmermann U, et al. Tailored Immunotherapy Approach With Nivolumab in Advanced Transitional Cell Carcinoma. J Clin Oncol 2022; 40:2128.</a></li><li><a class="nounderline abstract_t">Grimm MO, Grün CB, Niegisch G, et al. Tailored immunotherapy approach with nivolumab with or without ipilimumab in patients with advanced transitional cell carcinoma after platinum-based chemotherapy (TITAN-TCC): a multicentre, single-arm, phase 2 trial. Lancet Oncol 2023; 24:347.</a></li><li><a class="nounderline abstract_t">Serritella AV, Shenoy NK. Nivolumab Plus Ipilimumab vs Nivolumab Alone in Advanced Cancers Other Than Melanoma: A Meta-Analysis. JAMA Oncol 2023; 9:1441.</a></li><li><a class="nounderline abstract_t">Patel MR, Ellerton J, Infante JR, et al. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncol 2017.</a></li><li><a class="nounderline abstract_t">Powles T, van der Heijden MS, Castellano D, et al. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 2020; 21:1574.</a></li><li><a class="nounderline abstract_t">Powles T, Durán I, van der Heijden MS, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2018; 391:748.</a></li><li><a class="nounderline abstract_t">van der Heijden MS, Loriot Y, Durán I, et al. Atezolizumab Versus Chemotherapy in Patients with Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: A Long-term Overall Survival and Safety Update from the Phase 3 IMvigor211 Clinical Trial. Eur Urol 2021; 80:7.</a></li><li><a class="nounderline abstract_t">Powles T, Rosenberg JE, Sonpavde GP, et al. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. N Engl J Med 2021; 384:1125.</a></li><li><a class="nounderline abstract_t">Rosenberg JE, Powles T, Sonpavde GP, et al. EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma. Ann Oncol 2023; 34:1047.</a></li><li><a class="nounderline abstract_t">Rosenberg JE, O'Donnell PH, Balar AV, et al. Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy. J Clin Oncol 2019; 37:2592.</a></li><li><a class="nounderline abstract_t">Rosenberg J, Sridhar SS, Zhang J, et al. EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma. J Clin Oncol 2020; 38:1041.</a></li><li><a class="nounderline abstract_t">Petrylak DP, Powles T, Rosenberg JE. Enfortumab Vedotin in Advanced Urothelial Carcinoma. Reply. N Engl J Med 2021; 385:93.</a></li><li><a class="nounderline abstract_t">Yu EY, Petrylak DP, O'Donnell PH, et al. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial. Lancet Oncol 2021; 22:872.</a></li><li><a class="nounderline abstract_t">Tagawa ST, Balar AV, Petrylak DP, et al. TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors. J Clin Oncol 2021; 39:2474.</a></li><li class="breakAll">United States FDA Prescribing Label for Sacituzumab Govitecan https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761115s009lbl.pdf (Accessed on April 16, 2021).</li><li class="breakAll">Erdafitinib tablets. United States Prescribing Information. US National Library of Medicine. http://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212018s000lbl.pdf (Accessed on April 19, 2019).</li><li class="breakAll">US Food and Drug Administration (FDA). FDA List of cleared or approved companion diagnostic services (in-vitro and imaging tools). http://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools (Accessed on September 03, 2019).</li><li><a class="nounderline abstract_t">Loriot Y, Necchi A, Park SH, et al. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. N Engl J Med 2019; 381:338.</a></li><li><a class="nounderline abstract_t">Bahleda R, Italiano A, Hierro C, et al. Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors. Clin Cancer Res 2019; 25:4888.</a></li><li><a class="nounderline abstract_t">Siefker-Radtke AO, Necchi A, Park SH, et al. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study. Lancet Oncol 2022; 23:248.</a></li><li><a class="nounderline abstract_t">Nimgaonkar V, Hubbard RA, Carpenter EL, Mamtani R. Biomarker Testing, Treatment Uptake, and Survival Among Patients With Urothelial Cancer Receiving Gene-Targeted Therapy. JAMA Oncol 2022; 8:1070.</a></li><li><a class="nounderline abstract_t">Zheng X, Wang H, Deng J, et al. Safety and efficacy of the pan-FGFR inhibitor erdafitinib in advanced urothelial carcinoma and other solid tumors: A systematic review and meta-analysis. Front Oncol 2022; 12:907377.</a></li><li><a class="nounderline abstract_t">Loriot Y, Matsubara N, Park SH, et al. Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma. N Engl J Med 2023; 389:1961.</a></li><li><a class="nounderline abstract_t">Siefker-Radtke AO, Matsubara N, Park SH, et al. Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial. Ann Oncol 2024; 35:107.</a></li><li><a class="nounderline abstract_t">Bellmunt J, Théodore C, Demkov T, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009; 27:4454.</a></li><li><a class="nounderline abstract_t">Bellmunt J, Kerst JM, Vázquez F, et al. A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN). Ann Oncol 2017; 28:1517.</a></li><li><a class="nounderline abstract_t">Sweeney CJ, Roth BJ, Kabbinavar FF, et al. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol 2006; 24:3451.</a></li><li><a class="nounderline abstract_t">Galsky MD, Mironov S, Iasonos A, et al. Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. Invest New Drugs 2007; 25:265.</a></li><li><a class="nounderline abstract_t">Vaughn DJ, Broome CM, Hussain M, et al. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol 2002; 20:937.</a></li><li><a class="nounderline abstract_t">Ko YJ, Canil CM, Mukherjee SD, et al. Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study. Lancet Oncol 2013; 14:769.</a></li><li><a class="nounderline abstract_t">Pronzato P, Vigani A, Pensa F, et al. Second line chemotherapy with ifosfamide as outpatient treatment for advanced bladder cancer. Am J Clin Oncol 1997; 20:519.</a></li><li><a class="nounderline abstract_t">Sadeghi S, Quinn D, Dorff T, et al. EphrinB2 Inhibition and Pembrolizumab in Metastatic Urothelial Carcinoma. J Clin Oncol 2023; 41:640.</a></li><li><a class="nounderline abstract_t">Sternberg CN, Petrylak DP, Bellmunt J, et al. FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression. J Clin Oncol 2023; 41:629.</a></li><li><a class="nounderline abstract_t">Bamias A, Stenzl A, Brown SL, et al. Definition and Diagnosis of Oligometastatic Bladder Cancer: A Delphi Consensus Study Endorsed by the European Association of Urology, European Society for Radiotherapy and Oncology, and European Society of Medical Oncology Genitourinary Faculty. Eur Urol 2023; 84:381.</a></li><li><a class="nounderline abstract_t">Abufaraj M, Dalbagni G, Daneshmand S, et al. The Role of Surgery in Metastatic Bladder Cancer: A Systematic Review. Eur Urol 2018; 73:543.</a></li><li><a class="nounderline abstract_t">Bochner BH. Postchemotherapy Surgery for Advanced Urothelial Cancer: Another Tool To Improve Outcome. Eur Urol 2018; 73:558.</a></li></ol></div><div id="topicVersionRevision">Topic 3000 Version 104.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16034041" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10506615" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12209718" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17382149" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Prognostic factors for metastatic urothelial carcinoma treated with cisplatin and 5-fluorouracil-based regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1607913" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9215826" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12474531" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35039231" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Five and Ten-Year Outcomes of Neoadjuvant Chemotherapy and Surgery for High-Risk Upper Tract Urothelial Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20231682" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23206856" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36927002" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Novel Genetic Subtypes of Urothelial Carcinoma With Differential Outcomes on Immune Checkpoint Blockade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32900624" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The value and limitations of urothelial bladder carcinoma molecular classifications to predict oncological outcomes and cancer treatment response: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37341003" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Therapeutic responses to chemotherapy or immunotherapy by molecular subtype in bladder cancer patients: A meta-analysis and systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21376284" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21376284" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21376284" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : LBA6 EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37870949" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2189954" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2746745" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11870180" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2452983" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8371371" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A phase II study of methotrexate, vinblastine, doxorubicin and cisplatin plus recombinant human granulocyte-macrophage colony stimulating factors in patients with advanced transitional cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11352955" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16330205" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11001674" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37549482" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16319510" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Phase II study of gemcitabine and cisplatin in patients with advanced or metastatic bladder cancer: long-term follow-up of a 3-week regimen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12176787" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17851853" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Gemcitabine and cisplatin in locally advanced and metastatic bladder cancer; 3- or 4-week schedule?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23136231" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22370319" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36041086" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37369081" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22162575" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17207911" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15073851" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8625244" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11753976" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11408496" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15718315" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19396817" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14584068" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15685232" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31390274" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Phase II California Cancer Consortium Trial of Gemcitabine-Eribulin Combination in Cisplatin-Ineligible Patients With Metastatic Urothelial Carcinoma: Final Report (NCI-9653).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28967485" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32552471" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36494006" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2181313" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Biology and management of bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9053481" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8863548" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7525883" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9823976" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9164195" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9849481" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9396395" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28389316" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32940628" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients With Platinum-Refractory Metastatic Urothelial Cancer: The Canadian Cancer Trials Group BL.12 Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32940628" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients With Platinum-Refractory Metastatic Urothelial Cancer: The Canadian Cancer Trials Group BL.12 Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34051178" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27939400" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32416780" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38101433" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38101431" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38101431" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35926813" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32945632" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37071838" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After≥2 Years of Follow-Up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37071838" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After≥2 Years of Follow-Up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34893775" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37121850" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 subgroup analysis based on duration and cycles of 1L chemotherapy</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35654659" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35654659" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32271672" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32565133" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Final Overall Survival Analysis of the SOGUG Phase 2 MAJA Study: Maintenance Vinflunine Versus Best Supportive Care After First-Line Chemotherapy in Advanced Urothelial Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35960902" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : A Randomized, Double-Blind, Biomarker-Selected, Phase II Clinical Trial of Maintenance Poly ADP-Ribose Polymerase Inhibition With Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28212060" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29590008" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31050707" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of&gt;2 years of follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28131785" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31100038" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27733243" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33216356" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35275706" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Tailored Immunotherapy Approach With Nivolumab in Advanced Transitional Cell Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36868252" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Tailored immunotherapy approach with nivolumab with or without ipilimumab in patients with advanced transitional cell carcinoma after platinum-based chemotherapy (TITAN-TCC): a multicentre, single-arm, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37651124" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Nivolumab Plus Ipilimumab vs Nivolumab Alone in Advanced Cancers Other Than Melanoma: A Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29217288" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32971005" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29268948" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33902955" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Atezolizumab Versus Chemotherapy in Patients with Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: A Long-term Overall Survival and Safety Update from the Phase 3 IMvigor211 Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33577729" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37678672" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31356140" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32031899" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34192441" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Enfortumab Vedotin in Advanced Urothelial Carcinoma. Reply.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33991512" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33929895" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33929895" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33929895" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33929895" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31340094" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31088831" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35030333" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35551582" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Biomarker Testing, Treatment Uptake, and Survival Among Patients With Urothelial Cancer Receiving Gene-Targeted Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36776367" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Safety and efficacy of the pan-FGFR inhibitor erdafitinib in advanced urothelial carcinoma and other solid tumors: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37870920" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37871702" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19687335" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28419193" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16849761" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17146733" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11844814" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23706985" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9345341" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Second line chemotherapy with ifosfamide as outpatient treatment for advanced bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35984996" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : EphrinB2 Inhibition and Pembrolizumab in Metastatic Urothelial Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36240478" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37217391" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Definition and Diagnosis of Oligometastatic Bladder Cancer: A Delphi Consensus Study Endorsed by the European Association of Urology, European Society for Radiotherapy and Oncology, and European Society of Medical Oncology Genitourinary Faculty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29122377" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : The Role of Surgery in Metastatic Bladder Cancer: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29289404" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Postchemotherapy Surgery for Advanced Urothelial Cancer: Another Tool To Improve Outcome.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
